[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 404
1. Speel EJ, van de Wouw AJ, Claessen SM, Haesevoets A, Hopman AH, van der Wurff AA, Osieka R, Buettner R, Hillen HF, Ramaekers FC: Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma. Int J Cancer; 2008 Sep 15;123(6):1292-300

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular evidence for a clonal relationship between multiple lesions in patients with unknown primary adenocarcinoma.
  • Unknown primary adenocarcinoma (UPA) comprises a group of heterogeneous cancers of great clinical and biological interest.
  • UPA presents as metastatic disease without a detectable primary site after medical workup.
  • A molecular resemblance would argue for an early clonal outgrowth of tumor cells from the primary lesion, a mutual feature observed within this group of neoplasms.
  • The molecular data indicated that the multiple lesions in the 14 UPA patients, including the primary tumors, are clonally related.
  • In agreement with the theory of tumor progression, some metastatic lesions showed additional genetic alterations besides the characteristics that were shared with the primary tumor.
  • Our data provide molecular evidence for a clonal relationship between multiple metastases and the primary tumor within individual UPA patients, independent of the anatomical origin of the cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Neoplasm Metastasis / genetics. Neoplasms, Unknown Primary / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • (PMID = 18561313.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / CD44v6 antigen
  •  go-up   go-down


2. Hainsworth JD, Spigel DR, Thompson DS, Murphy PB, Lane CM, Waterhouse DM, Naot Y, Greco FA: Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site. Oncologist; 2009 Dec;14(12):1189-97
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
  • INTRODUCTION: This phase II trial evaluated the efficacy and toxicity of the combination of paclitaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with carcinoma of unknown primary site (CUP).
  • METHODS: Patients with previously untreated CUP (adenocarcinoma, poorly differentiated carcinoma, poorly differentiated squamous carcinoma) without clinical or pathologic characteristics of a well-defined treatable subset were eligible.
  • CONCLUSIONS: Empiric treatment with paclitaxel, carboplatin, bevacizumab, and erlotinib is effective and well tolerated as first-line treatment for patients with CUP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Humanized. Bevacizumab. Carboplatin / administration & dosage. Carboplatin / adverse effects. Carcinoma / drug therapy. Carcinoma, Squamous Cell / drug therapy. Disease-Free Survival. Erlotinib Hydrochloride. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Quinazolines / administration & dosage. Quinazolines / adverse effects. Survival Rate. Young Adult

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965914.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 2S9ZZM9Q9V / Bevacizumab; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


3. Buc E, Lesurtel M, Belghiti J: Is preoperative histological diagnosis necessary before referral to major surgery for cholangiocarcinoma? HPB (Oxford); 2008;10(2):98-105

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Provided that between 8% and 43% of bile duct strictures are not ECC, the lesions mimicking ECC that should be ruled out are gallbladder cancer, Mirizzi syndrome, primary sclerosing cholangitis (PSC), autoimmune pancreatitis and portal biliopathy.
  • The lack of the primary site, a relatively large tumour size and ancillary findings such as bile duct dilatation may provide a clue to the diagnosis.
  • In the event of adenocarcinoma from unknown primary, surgery is an effective treatment even if prognosis is poor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 1994 Mar-Apr;40(2 Pt 1):150-4 [8013812.001]
  • [Cites] Am J Gastroenterol. 1995 May;90(5):722-6 [7733076.001]
  • [Cites] Virchows Arch. 1995;426(2):209-13 [7757293.001]
  • [Cites] Int Surg. 1995 Jan-Mar;80(1):61-4 [7657495.001]
  • [Cites] Radiology. 1996 Apr;199(1):91-8 [8633178.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):520-6 [8674921.001]
  • [Cites] Gastrointest Endosc. 1995 Dec;42(6):565-72 [8674929.001]
  • [Cites] Abdom Imaging. 1997 Jan-Feb;22(1):87-90 [9000364.001]
  • [Cites] Gut. 1997 May;40(5):671-7 [9203949.001]
  • [Cites] Eur Radiol. 1997;7(6):865-74 [9228102.001]
  • [Cites] Gastrointest Endosc. 1998 Sep;48(3):288-90 [9744607.001]
  • [Cites] Surgery. 1999 May;125(5):514-21 [10330940.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):43-4 [10406367.001]
  • [Cites] N Engl J Med. 1962 Jan 11;266:57-61 [13877392.001]
  • [Cites] Arch Surg. 1962 Sep;85:503-13 [13887615.001]
  • [Cites] Br J Surg. 1965 Feb;52:129-39 [14255983.001]
  • [Cites] Gastrointest Endosc. 2004 Dec;60(6):1021-4 [15605028.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2005;12(2):159-62 [15868083.001]
  • [Cites] Dig Dis Sci. 2005 Sep;50(9):1734-40 [16133981.001]
  • [Cites] Am J Clin Pathol. 2005 Sep;124(3):355-60 [16191503.001]
  • [Cites] Endoscopy. 1999 Nov;31(9):712-7 [10604612.001]
  • [Cites] J Gastrointest Surg. 2002 Sep-Oct;6(5):676-81 [12399056.001]
  • [Cites] Gastrointest Endosc. 1996 May;43(5):498-502 [8726766.001]
  • [Cites] Gut. 1996 Apr;38(4):610-5 [8707097.001]
  • [Cites] Lancet. 2005 Oct 8;366(9493):1303-14 [16214602.001]
  • [Cites] J Am Coll Surg. 2005 Dec;201(6):862-9 [16310689.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):71-7 [16377319.001]
  • [Cites] Gastroenterol Clin Biol. 2005 Dec;29(12):1224-32 [16518276.001]
  • [Cites] Gastrointest Endosc. 1999 Nov;50(5):646-52 [10536320.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Gastrointest Endosc. 2003 Aug;58(2):176-82 [12872082.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):658-61 [14511613.001]
  • [Cites] Ann Surg Oncol. 2004 Mar;11(3):310-5 [14993027.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Mar;2(3):209-13 [15017604.001]
  • [Cites] World J Surg. 2004 May;28(5):466-70 [15085401.001]
  • [Cites] Semin Liver Dis. 2004 May;24(2):115-25 [15192785.001]
  • [Cites] Am Surg. 2004 Jun;70(6):512-7 [15212405.001]
  • [Cites] Am J Gastroenterol. 2004 Aug;99(8):1464-9 [15307861.001]
  • [Cites] Gastrointest Endosc. 2004 Sep;60(3):390-6 [15332029.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):1008-9 [15362064.001]
  • [Cites] Abdom Imaging. 2004 Sep-Oct;29(5):548-57 [15185025.001]
  • [Cites] ANZ J Surg. 2004 Oct;74(10):826 [15456420.001]
  • [Cites] Hepatology. 2006 Sep;44(3):746-64 [16941705.001]
  • [Cites] Hepatology. 2006 Nov;44(5):1063-74 [17058222.001]
  • [Cites] Surgery. 2006 Nov;140(5):756-63 [17084718.001]
  • [Cites] AJR Am J Roentgenol. 2007 Apr;188(4):W341-7 [17377002.001]
  • [Cites] Ann Surg. 2007 May;245(5):755-62 [17457168.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):770-5 [17594717.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1781-8 [17509029.001]
  • [Cites] Hepatogastroenterology. 2007 Jul-Aug;54(77):1517-21 [17708288.001]
  • [Cites] Radiographics. 2008 Jan-Feb;28(1):157-70 [18203936.001]
  • [Cites] Hepatogastroenterology. 2007 Oct-Nov;54(79):2146-51 [18251178.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1147-54 [18219538.001]
  • [Cites] Arch Pathol Lab Med. 2000 Mar;124(3):387-92 [10705391.001]
  • [Cites] Gastrointest Endosc. 2000 Apr;51(4 Pt 1):383-90 [10744806.001]
  • [Cites] Gastrointest Endosc. 2000 Oct;52(4):534-40 [11023576.001]
  • [Cites] Br J Surg. 2001 Jan;88(1):48-51 [11136309.001]
  • [Cites] Acta Gastroenterol Belg. 2000 Jul-Sep;63(3):254-9 [11189981.001]
  • [Cites] J Clin Pathol. 2001 Jun;54(6):449-55 [11376018.001]
  • [Cites] Am J Gastroenterol. 2001 Aug;96(8):2520-2 [11513216.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Oct;16(10):1086-92 [11686833.001]
  • [Cites] Abdom Imaging. 2002 Jan-Feb;27(1):58-60 [11740610.001]
  • [Cites] Gut. 2002 Nov;51 Suppl 6:VI1-9 [12376491.001]
  • [Cites] Gastrointest Endosc. 2002 Nov;56(5):720-30 [12397282.001]
  • [Cites] Am J Surg. 1973 Jun;125(6):782-5 [4710205.001]
  • [Cites] Ann Surg. 1978 Nov;188(5):593-7 [82427.001]
  • [Cites] J Comput Assist Tomogr. 1983 Oct;7(5):902-4 [6886144.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):659-61 [4027545.001]
  • [Cites] Ann Intern Med. 1986 Aug;105(2):207-10 [3014940.001]
  • [Cites] Am J Surg Pathol. 1988 Sep;12(9):708-15 [3046396.001]
  • [Cites] Ann Radiol (Paris). 1988;31(5):309-11 [3202598.001]
  • [Cites] Br J Surg. 1989 Aug;76(8):849-52 [2765843.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1583-90 [2155699.001]
  • [Cites] Am J Gastroenterol. 1991 May;86(5):577-80 [2028947.001]
  • [Cites] Hum Pathol. 1991 Apr;22(4):387-95 [2050373.001]
  • [Cites] Bull Cancer. 1991;78(8):725-36 [1932839.001]
  • [Cites] Gastrointest Endosc. 1992 Jan-Feb;38(1):35-9 [1612376.001]
  • [Cites] Surgery. 1992 Nov;112(5):866-71 [1332203.001]
  • [Cites] Hepatology. 1993 May;17(5):807-13 [8491448.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):261-7 [7684858.001]
  • [Cites] Abdom Imaging. 1993;18(3):245-6 [8508085.001]
  • [Cites] N Engl J Med. 1993 Jul 22;329(4):257-63 [8316270.001]
  • [Cites] Mayo Clin Proc. 1993 Sep;68(9):874-9 [8396700.001]
  • [Cites] Hum Pathol. 1994 Jan;25(1):86-91 [8314264.001]
  • (PMID = 18773064.001).
  • [ISSN] 1365-182X
  • [Journal-full-title] HPB : the official journal of the International Hepato Pancreato Biliary Association
  • [ISO-abbreviation] HPB (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2504385
  •  go-up   go-down


Advertisement
4. Todoroki T, Murata S, Nakagawa Y, Ohkohchi N, Morishita Y: A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. Int Semin Surg Oncol; 2006;3:22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report.
  • BACKGROUND: Tumor spread beyond the peritoneal cavity in cases of papillary serous adenocarcinoma of the unknown primary (CUP) is a rare late event and carries a poor prognosis.
  • Pathological examination revealed the tumors to be metastases of a papillary serous adenocarcinoma with a psammoma body of CUP.
  • Four and a half years after the primary resection, the CA125 level increased again and newly developed asymptomatic metastases were found in the right deep inguinal nodes and extirpated at that time.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):16-20 [11301835.001]
  • [Cites] Jpn J Cancer Res. 2001 Jun;92(6):704-9 [11429061.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1003-10 [14997197.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):443-9 [15816609.001]
  • [Cites] DICP. 1990 Mar;24(3):289-95 [2138376.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1091-4 [2400962.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):15-21 [9210704.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • (PMID = 16930493.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574334
  •  go-up   go-down


5. Kumar R, Deopujari CE, Shah R, Kumar A: Metastatic adenocarcinoma of bilateral cavernous sinus and optic nerve with unknown primary mimicking orbital pseudotumor. Neurol India; 2009 Jan-Feb;57(1):82-4
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adenocarcinoma of bilateral cavernous sinus and optic nerve with unknown primary mimicking orbital pseudotumor.
  • We report an extremely rare case of metastatic adenocarcinoma of bilateral cavernous sinus and optic nerve with unknown primary presenting as orbital pseudotumor.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Brain Neoplasms / secondary. Cavernous Sinus / pathology. Optic Nerve Neoplasms / pathology. Optic Nerve Neoplasms / secondary. Orbital Pseudotumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19305087.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


6. Greco FA: Therapy of adenocarcinoma of unknown primary: are we making progress? J Natl Compr Canc Netw; 2008 Nov;6(10):1061-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of adenocarcinoma of unknown primary: are we making progress?
  • Therapy for patients with unknown primary carcinoma is evolving and requires a detailed understanding of the various clinicopathologic subsets with more favorable prognoses.
  • The survival of patients with several metastatic adenocarcinomas of known primary sites, including colon/rectum, lung, and pancreas, has been improved by the administration of chemotherapy alone or combined with biologic targeted drugs (bevacizumab, erlotinib).
  • Approximately 60% of the patients with unknown primary adenocarcinoma have clinically occult primary sites of colon/rectum, lung, and pancreas.
  • Many of these patients will also benefit from therapeutic regimens now proven to be useful for patients with these known primary sites.
  • All available data make a convincing argument that progress is being made for the commonly seen patients with adenocarcinoma of unknown primary site, and is likely to continue as understanding of these and other neoplasms further evolves.
  • [MeSH-major] Adenocarcinoma / therapy. Neoplasms, Unknown Primary / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19176201.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 48
  •  go-up   go-down


7. Bordel Gómez MT, Used Aznar MM: [Cutaneous metastases from adenocarcinoma of unknown primary site]. Actas Dermosifiliogr; 2006 Dec;97(10):662-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cutaneous metastases from adenocarcinoma of unknown primary site].
  • [Transliterated title] Metástasis cutáneas de adenocarcinoma de origen primario desconocido.
  • Metastatic cancer of unknown primary site appears in 5-10% of oncologic patients.
  • The primary tumor is usually discovered at autopsy and only in 27% of patients alive.
  • Metastases from cancer of unknown primary site may be located in the skin and subcutaneous tissue and it is the dermatologist the first in evaluating these patients.
  • We present a case of cutanoeus metastases from moderately-differentiated adenocarcinoma of unknown primary site.
  • The primary tumor could not be identified in spite of the imaging and endoscopic studies performed.
  • Based on these studies we excluded a colorectal or prostatic origin and considered a pancreatic adencarcinoma as the possible primary tumor.
  • Even though a minority of these patients will have a curable disease, the appropriate use of pathological diagnosis and selected imaging studies for an optimal management of patients with a tumor of unknown primary site should not be ignored.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasms, Unknown Primary. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173831.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 17
  •  go-up   go-down


8. Spurgeon JM, Cotlar AM: Cytoreductive surgery in the management of malignant ascites from adenocarcinoma of unknown primary (ACUP). Curr Surg; 2005 Sep-Oct;62(5):500-3
MedlinePlus Health Information. consumer health - Palliative Care.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytoreductive surgery in the management of malignant ascites from adenocarcinoma of unknown primary (ACUP).
  • A case report is presented of a 62-year-old man with adenocarcinoma of unknown primary (ACUP) who was admitted with massive ascites from intraperitoneal carcinomatosis secondary to a gastrointestinal tract malignancy.
  • [MeSH-major] Adenocarcinoma / therapy. Chemotherapy, Cancer, Regional Perfusion / methods. Neoplasm Invasiveness / pathology. Neoplasms, Unknown Primary / pathology. Palliative Care. Peritoneal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125606.001).
  • [ISSN] 0149-7944
  • [Journal-full-title] Current surgery
  • [ISO-abbreviation] Curr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


9. Shibata K, Kametani T, Takase M, Chatani K, Masuda S: [A case of adenocarcinoma of unknown primary site successfully treated with gemcitabine monotherapy]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1489-92
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adenocarcinoma of unknown primary site successfully treated with gemcitabine monotherapy].
  • A 68-year-old female diagnosed with adenocarcinoma of unknown primary site (ACUP) by biopsy of supraclavicular lymph node was admitted to our department because of progressive dyspnea with cough.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / secondary. Neoplasms, Unknown Primary / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033244.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / DU-PAN-2 antigen, human; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


10. El-Rayes BF, Shields AF, Zalupski M, Heilbrun LK, Jain V, Terry D, Ferris AM, Philip PA: A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary. Am J Clin Oncol; 2005 Apr;28(2):152-6
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
  • BACKGROUND: Cisplatin-based combination chemotherapy is commonly used in the treatment of carcinoma of unknown primary site.
  • This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with adenocarcinoma of unknown primary site (ACUP).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15803009.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-22453
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Power D, Lagunes DR: Adenocarcinoma of unknown primary in a 20-year-old African American male. Clin Genitourin Cancer; 2009 Aug;7(2):E45-8
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of unknown primary in a 20-year-old African American male.
  • Lung biopsy revealed poorly differentiated adenocarcinoma positive for cytokeratin 7.
  • By exclusion, it appeared that the patient had a carcinoma of unknown primary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Kidney Medulla / pathology. Kidney Neoplasms / diagnosis. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19692325.001).
  • [ISSN] 1938-0682
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Sorgho-Lougue LC, Luciani A, Kobeiter H, Zelek L, Malhaire C, Deux JF, Brun B, Piedbois P, Rahmouni A: Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up. Eur J Radiol; 2006 Jul;59(1):42-8
Genetic Alliance. consumer health - Diagnosis Unknown.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinomas of unknown primary (ACUP) of the mediastinum mimicking lymphoma: CT findings at diagnosis and follow-up.
  • OBJECTIVE: To describe the computed tomography (CT) features at diagnosis and after treatment of adenocarcinoma of unknown primary (ACUP) mimicking lymphoma of the mediastinum.
  • [MeSH-major] Adenocarcinoma / radiography. Adenocarcinoma / secondary. Mediastinal Neoplasms / radiography. Mediastinal Neoplasms / secondary. Neoplasms, Unknown Primary / radiography. Tomography, Spiral Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504446.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


13. Dimitroulas T, Settas L: Paget's disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report. Eur J Gynaecol Oncol; 2009;30(4):458-9
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paget's disease of the vulva in a patient with scleroderma and underlying adenocarcinoma: case report.
  • The patient underwent radical vulvectomy, but 18 months later died due to adenocarcinoma of unknown primary origin.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasms, Multiple Primary. Neoplasms, Unknown Primary. Paget Disease, Extramammary / complications. Scleroderma, Systemic / complications. Vulvar Neoplasms / complications

  • Genetic Alliance. consumer health - Scleroderma.
  • MedlinePlus Health Information. consumer health - Scleroderma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19761147.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


14. Strickland-Marmol LB, Khoor A, Livingston SK, Rojiani A: Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain. Arch Pathol Lab Med; 2007 Nov;131(11):1686-90
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of tissue-specific transcription factors thyroid transcription factor 1 and Cdx2 in determining the primary site of metastatic adenocarcinomas to the brain.
  • CONTEXT: Brain metastases of adenocarcinoma of unknown primary pose a diagnostic dilemma to the surgical pathologist.
  • Although the most common source in these cases is the lung, determining a primary source is difficult on routinely stained slides.
  • Lee Moffitt Cancer Center and Research Institute, Tampa, Fla, and retrieved 38 consecutive cases of metastatic adenocarcinoma (22 pulmonary, 10 breast, 6 gastrointestinal [2 esophagus/gastroesophageal junction, 4 colorectal]) to the brain with confirmation of the primary site by chart review and histologic evaluation.
  • CONCLUSIONS: Cdx2 is a specific and valuable tool for the surgical pathologist when faced with the common problem of metastatic adenocarcinoma of unknown primary.
  • In conjunction with TTF-1, cytokeratin 7, and cytokeratin 20, Cdx2 can accurately differentiate the most common sources of metastatic adenocarcinoma to the brain.
  • [MeSH-major] Adenocarcinoma / secondary. Brain Neoplasms / secondary. DNA-Binding Proteins / metabolism. Homeodomain Proteins / metabolism. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17979487.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / DNA-Binding Proteins; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / TTF1 protein, human
  •  go-up   go-down


15. Fukuoka M, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N, Watkins C, Duffield E, Armour A, Mok T: Biomarker analyses from a phase III, randomized, open-label, first-line study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol; 2009 May 20;27(15_suppl):8006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8006^ Background: IPASS demonstrated overall superiority of first-line G vs C/P for progression-free survival (PFS) in never/light ex-smokers with stage IIIB/IV adenocarcinoma NSCLC in Asia.
  • Analyses included primary endpoint PFS (Cox proportional hazards) and secondary endpoint objective response rate (ORR; logistic regression) by biomarker status.
  • In M unknown pts PFS and ORR were similar to overall population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962786.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Gandara D, Kim ES, Herbst RS, Moon J, Redman MW, Dakhil SR, Hirsch F, Mack PC, Franklin W, Kelly K: S0536: Carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab maintenance in advanced non-small cell lung cancer (NSCLC): A SWOG phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):8015

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary endpoint: feasibility defined by the frequency and severity of ≥grade 4 hemorrhagic toxicities.
  • Pt characteristics: median age 64 years (42-78), Male/Female 52/52, PS 0/1 43/61, stage IIIB/IV 9/95, adenocarcinoma: 81, current/former smoker: 82.
  • Primary endpoint was met: grade ≥4 hemorrhage: 2% (95% CI: 0-7%).
  • There were 4 treatment-related deaths: lung hemorrhage (2), infection (1), unknown (1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962808.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Jhawer M, Kindler HL, Wainberg Z, Ford J, Kunz P, Tang L, McCallum S, Kallender H, Shah MA, MET111643 Investigators and GlaxoSmithKline: Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study. J Clin Oncol; 2009 May 20;27(15_suppl):4502

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Pts with distal esophagus, GE junction or stomach adenocarcinoma, 0-2 prior chemotherapy regimens, adequate organ function, measurable disease, and ECOG PS 0-2 are sequentially enrolled in 2 cohorts:.
  • Primary study endpoint (response) is assessed every 8 weeks. cMET amplification by FISH (≥2 copies of cMET per copy of chromosome 7) is not an entry criterion, but is determined on archival tissue for all pts.
  • Only 1 possibly related grade 5 AE, death due to unknown cause, was noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962690.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Lujan M, Cardona AF, Yepes A, Carrasco-Chaumel E, Reveiz L, Otero JM: Myelophthisis in solid tumors: Old aspects, new concepts (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e20672

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Twenty-seven pts (30%) had breast cancer, pathology followed by primary unknown tumours (21%), rabdomiosarcoma (10%), prostate adenocarcinoma (10%), gastric carcinoma (7%) and others (22%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Yap JC, Yang GY, Fakih M, Mashtare T, Bullard Dunn K, Kuvshinoff BW, Smith J, Khushalani NI, Gibbs JF: Primary adenocarcinoma of the anus: a 22-year SEER population database analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e15072

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the anus: a 22-year SEER population database analysis.
  • Adenocarcinoma (AdenoCa) is rare and accounts for approximately 10% of anal cancers.
  • Excluded were pts with unknown use of surgery or radiation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964572.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hainsworth JD, Lane C, Spigel DR, Shipley D, Waterhouse D, Bury M, Greco FA: Randomized phase III comparison of paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan, both followed by gefitinib, in patients (pts) with carcinoma of unknown primary site (CUP). J Clin Oncol; 2009 May 20;27(15_suppl):4631

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase III comparison of paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan, both followed by gefitinib, in patients (pts) with carcinoma of unknown primary site (CUP).
  • : 4631 Background: Empiric chemotherapy for pts with CUP has resulted in modest survival improvements.
  • METHODS: Previously untreated pts with CUP (adenocarcinoma, poorly differentiated adenocarcinoma, poorly differentiated carcinoma, poorly differentiated squamous carcinoma) were eligible.
  • The primary endpoint was the 2-year survival rate.
  • CONCLUSIONS: The PCE and GI regimens had comparable efficacy in the treatment of CUP, while the GI regimen was better tolerated.
  • Better treatments are needed for pts with CUP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964228.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hu M, Yu J, Liu N, Kong L, Zhang P: The role of whole body <sup>18</sup>F-FDG PET/CT scan in patients with carcinoma of unknown primary. J Clin Oncol; 2009 May 20;27(15_suppl):e22051

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of whole body <sup>18</sup>F-FDG PET/CT scan in patients with carcinoma of unknown primary.
  • : e22051 Background: Carcinoma of unknown primary (CUP) is a heterogeneous group of tumors and usually follows an aggressive biological and clinical behavior.
  • Difficult challenges in oncology which the identification of the primary tumor and a complete disease staging could offer a more rational and efficient treatment in order to improve the survival time.
  • Our aim was to evaluate the role of <sup>18</sup>F-FDG PET/CT scan with two aspects: detection of the primary site, and estimation of tumor biological behavior which essential for the development of new, individual and targeted effective therapies.
  • METHODS: One hundred and seventeen patients presenting with histologically confirmed metastatic carcinoma (76 lymph nodes, 41 visceral biopsy proven) of unknown primary site were included in this retrospective study.
  • The evaluations as follows had not revealed a primary site: detailed medical history, full physical and laboratory examinations, and diagnostic imaging methods.
  • RESULTS: In 42 (35.90%) patients, a primary tumor site which was confirmed by follow-up or surgery was showed by PET/CT.
  • In 15 (12.82%) patients, the primary tumor site was suggested by PET/CT but not confirmed.
  • In 60 (51.28%) patients, the primary tumor site was not localized modifying the stage of disease.
  • Between the adenocarcinoma and squamous cell carcinoma groups, no significant difference in SUVmax was found ( t=1.191, p = 0.244).
  • A significantly higher SUVmax was found among patients with poorly or undifferentiated carcinoma compared with patients with well to moderately ( t=4.013, p<0.01) differentiation; In 42 patients with a confirmed primary tumor site, the SUVmax of Metastatic tumours have a closely relationship correlate with those of primary tumours, ( r=0.738, p<0.01).
  • Furthermore, a significantly higher SUVmax was found among metastases compared with primary tumors ( t=3.470, p<0.01).
  • CONCLUSIONS: Our data strongly support <sup>18</sup>F-FDG PET/ CT imagings not only provide new insights in the diagnosis and staging of patients with CUP, but also evaluate biologic characters of tissue.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963233.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Gutiérrez Macías A, Lizarralde Palacios E, Merino Múgica JM, Cabeza García S, Martínez Odriozola P, Miguel de la Villa F: [Bilateral chylothorax in a case of metastatic adenocarcinoma of unknown primary]. An Med Interna; 2006 Apr;23(4):176-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral chylothorax in a case of metastatic adenocarcinoma of unknown primary].
  • [Transliterated title] Quilotórax bilateral en un caso de adenocarcinoma metastásico de primario desconocido.
  • Necropsy showed widespread metastatic adenocarcinoma of unknown primary.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Chylothorax / etiology. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16796411.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


23. Adachi Y, Nakamura H, Nitta S: [Mediastinal lymph node adenocarcinoma with unknown primary site; report of a case]. Kyobu Geka; 2006 Jul;59(7):597-601

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal lymph node adenocarcinoma with unknown primary site; report of a case].
  • In the histological diagnosis, there were no malignant finding in the right lung, and mediastinal lymph nodes showed poorly differentiated adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Lymph Node Excision. Lymph Nodes / pathology. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856539.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


24. Xambre L, Cerqueira M, Cardoso A, Correia T, Macedo Dias A, Carreira F, Galán T: [Primary mucinous adenocarcinoma of the renal pelvis--adicional case report]. Actas Urol Esp; 2009 Feb;33(2):200-4
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary mucinous adenocarcinoma of the renal pelvis--adicional case report].
  • [Transliterated title] Adenocarcinoma mucinoso primário de pélvis renal--caso adicional.
  • Mucinous adenocarcinoma of the renal pelvis may be classified as among the rarest neoplasms of the genitourinary tract.
  • Despite the known association with chronic inflammatory conditions of the upper urinary tract, the exact pathogenesis remains unknown.
  • [MeSH-major] Adenocarcinoma, Mucinous. Kidney Neoplasms. Kidney Pelvis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418847.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 13
  •  go-up   go-down


25. Pawar A, Schlader E, Mac-Thiong JM, Maurais G, Dion D, Bédard D: Rare metastatic adenocarcinoma to the spine infiltrating three adjacent foramen in lumbar vertebrae. Orthopedics; 2010 Dec;33(12):928

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare metastatic adenocarcinoma to the spine infiltrating three adjacent foramen in lumbar vertebrae.
  • Computed tomography-guided biopsy confirmed the diagnosis of metastatic adenocarcinoma.
  • However, the primary site could not be found despite several investigations.
  • It is usually thought that the primary tumor spreads to the spine through the valveless Batson's plexus or by direct arterial seeding into vertebral bodies.
  • A paravertebral primary tumor such as a lymphoma, a primary tumor from the lungs, or a renal cell carcinoma can potentially infiltrate the vertebral bodies and enter the spinal canal through the neural foramen.
  • But a large retroperitoneal metastatic mass from an unknown primary adenocarcinoma is a rare condition.
  • Thus, the pathogenesis of metastatic adenocarcinomas, particularly when the primary site is unknown, is not completely understood and can give a varied radiological presentation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Lumbar Vertebrae / pathology. Lumbar Vertebrae / surgery. Spinal Neoplasms / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010, SLACK Incorporated.
  • (PMID = 21162500.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Sarbia M, Fritze F, Geddert H, von Weyhern C, Rosenberg R, Gellert K: Differentiation between pancreaticobiliary and upper gastrointestinal adenocarcinomas: is analysis of cytokeratin 17 expression helpful? Am J Clin Pathol; 2007 Aug;128(2):255-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic adenocarcinoma of unknown primary site, eg, to lymph nodes, liver, or lung, may originate from many organs.
  • A high prevalence of cytokeratin (CK)17 expression in pancreaticobiliary adenocarcinoma was reported, and preliminary data indicate infrequent or missing expression in gastric adenocarcinoma.
  • CK17 expression was as follows: pancreatic, 88%; bile duct, 59%; esophageal, 30%; distal gastric, 28%; gastric cardiac, 27%; and colorectal adenocarcinoma, 6%.
  • These differences were statistically significant for all tumor types except in comparisons of esophageal, cardiac, and distal gastric adenocarcinoma.
  • However, in individual cases of adenocarcinoma of unknown primary site, CK17 results alone are insufficient to differentiate the analyzed tumor entities.
  • [MeSH-major] Adenocarcinoma / chemistry. Bile Duct Neoplasms / chemistry. Gastrointestinal Neoplasms / chemistry. Keratin-17 / analysis. Pancreatic Neoplasms / chemistry

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638659.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Ghosh SB, Tempe A: Retroperitoneal adenocarcinoma of unknown origin presenting as a rare cause of obstructed labor. Arch Gynecol Obstet; 2009 Mar;279(3):427-9
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retroperitoneal adenocarcinoma of unknown origin presenting as a rare cause of obstructed labor.
  • BACKGROUND: Metastatic retroperitoneal adenocarcinoma presenting as obstructed labor is extremely rare.
  • A diagnosis of retroperitoneal adenocarcinoma with an unknown primary was made based on histopathology and a negative workup for the possible primary sites.
  • [MeSH-major] Adenocarcinoma / complications. Dystocia / etiology. Pregnancy Complications, Neoplastic / pathology. Retroperitoneal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665376.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Horlings HM, van Laar RK, Kerst JM, Helgason HH, Wesseling J, van der Hoeven JJ, Warmoes MO, Floore A, Witteveen A, Lahti-Domenici J, Glas AM, Van't Veer LJ, de Jong D: Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol; 2008 Sep 20;26(27):4435-41
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
  • PURPOSE: Patients with adenocarcinoma of unknown primary origin (ACUP) constitute approximately 4% of all malignancies.
  • For effective treatment of these patients, it is considered optimal to identify the primary tumor origins.
  • PATIENTS AND METHODS: Formalin-fixed, paraffin-embedded (FFPE) samples were obtained from 84 patients with a known primary adenocarcinoma and from 38 patients with ACUP.
  • RESULTS: The gene expression-based assay classified the primary site correctly in 70 (83%) of 84 patient cases of primary and metastatic tumors of known origin, with good sensitivity for the majority of the tumor classes and relatively poor sensitivity for primary lung adenocarcinoma.
  • CONCLUSION: The gene expression platform can classify correctly from FFPE samples the majority of tumors classes both in patients with known primary and in patients with ACUP.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Gene Expression Profiling. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 Feb 1;27(4):649-50; author reply 650-2 [19114684.001]
  • [CommentIn] J Clin Oncol. 2008 Sep 20;26(27):4373-5 [18802148.001]
  • (PMID = 18802156.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


29. Jariengprasert C, Laothamatas J, Janwityanujit T, Phudhichareonrat S: Bilateral sudden sensorineural hearing loss as a presentation of metastatic adenocarcinoma of unknown primary mimicking cerebellopontine angle tumor on the magnetic resonance image. Am J Otolaryngol; 2006 Mar-Apr;27(2):143-5
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sudden sensorineural hearing loss as a presentation of metastatic adenocarcinoma of unknown primary mimicking cerebellopontine angle tumor on the magnetic resonance image.
  • Surgical biopsy and histopathologic finding identified masses secondary to direct invasion of adenocarcinoma of gastrointestinal origin.
  • Many investigations could not discover the primary site of the metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cerebellar Neoplasms / diagnosis. Cerebellopontine Angle / pathology. Hearing Loss, Sensorineural / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Middle Aged. Neoplasms, Unknown Primary

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500481.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Martin SK, Agarwal G, Lynch GR: Subcutaneous fat necrosis as the presenting feature of a pancreatic carcinoma: the challenge of differentiating endocrine and acinar pancreatic neoplasms. Pancreas; 2009 Mar;38(2):219-22
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous pathological evaluation of the patient's liver biopsy led to an initial diagnosis of adenocarcinoma of unknown primary site.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19238022.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Hill HC: Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma. J Natl Med Assoc; 2008 Dec;100(12):1469-73
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges of utilizing immunostains to facilitate the diagnosis and management of metastatic adenocarcinoma.
  • Women presenting with metastases from an unknown primary site represent a growing diagnostic challenge.
  • Treatment is based upon the results of several diagnostic radiographic modalities that may locate the occult primary and determine the extent of metastatic tumor burden.
  • Immunostaining represents another modality that can be used to facilitate identification and management of occult primary carcinoma.
  • We describe metastatic adenocarcinoma of unknown primary presenting as a pericardial effusion and coincident supraclavicular adenopathy.
  • Although immunohistochemical staining initially suggested metastatic breast carcinoma, her clinical course confirmed a lung primary.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Natl Med Assoc. 2009 May;101(5):478 [19476202.001]
  • (PMID = 19110917.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q1J152VB1P / Bromhexine
  •  go-up   go-down


32. Stakia P, Lagos P, Gourgiotis S, Tzilalis VD, Aloizos S, Salemis NS: Large mass affecting retroperitoneal great vessels: a rare presentation of a cancer of unknown primary with diagnostic dilemma and challenged surgical intervention. J Gastrointest Cancer; 2009;40(1-2):55-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mass affecting retroperitoneal great vessels: a rare presentation of a cancer of unknown primary with diagnostic dilemma and challenged surgical intervention.
  • INTRODUCTION: Cancers of unknown primary site (CUPs) consist of a clinical entity which accounts for 3-5% of all solid tumor patients.
  • They are metastatic solid tumors whose fundamental characteristic is the absence of identifiable site of the primary tumor.
  • A complete resection of the mass was performed while the histological examination revealed a solitary retroperitoneal lymph node categorized as metastatic adenocarcinoma of unknown primary site.
  • CONCLUSION: It is essential to assess the high incidence of patients with cancer who present with CUP.
  • [MeSH-major] Adenocarcinoma / secondary. Blood Vessels / pathology. Neoplasms, Unknown Primary / pathology. Retroperitoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Oncologist. 2007 Apr;12(4):418-25 [17470684.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):535-40 [11398889.001]
  • [Cites] Br J Cancer. 2004 May 17;90(10):1898-904 [15138469.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):840-6 [11857320.001]
  • [Cites] Oncologist. 1997;2(3):142-152 [10388044.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] Cancer J. 2001 May-Jun;7(3):203-12 [11419028.001]
  • [Cites] Med Clin North Am. 1996 Jan;80(1):153-71 [8569295.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1810-2 [12175699.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • (PMID = 19513858.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Eickhoff A, Spiethoff A, Hartmann D, Jakobs R, Weickert U, Schilling D, Eickhoff JC, Bohrer MH, Riemann JF: [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site]. Dtsch Med Wochenschr; 2007 Feb 23;132(8):369-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Space-occupying lesions in the liver: incidence of adenocarcinoma metastases of unknown primary site].
  • BACKGROUND AND OBJECTIVE: The diagnostic approach to newly detected space-occupying lesions in the liver can be difficult and a histogenetic classification of the primary tumor is impossible in some cases.
  • Such cases of metastatic disease without a detectable primary tumor are classified as cancer of unknown primary site (CUP).
  • It was the main aim of this study to analyze the true incidence of adenocarcinoma metastases of the liver with an unknown primary cancer after application of a standardized protocol of clinical and immunhistochemical diagnostic tests and a long-term follow-up.
  • Primary tumors of the liver were found in 21 cases and non-hepatocellular tumors (metastases) were documented in 106 patients, 82 of the latter (77%) had metastases of an adenocarcinoma.
  • The further diagnostic approach was based on histochemistry, immunhistochemistry and imaging techniques, making possible a full diagnosis of primary tumor in a further 59 (72%) cases.
  • Thus the incidence of an adenocarcinoma of the liver of unknown primary site was 23 of 127 cases (18%).
  • [MeSH-major] Adenocarcinoma / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17299675.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ: Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. Am J Clin Oncol; 2008 Feb;31(1):1-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three objective tumor responses were noted (squamous cell of anus, adenocarcinoma of unknown primary, adenocarcinoma of rectum).

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376220.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006927
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Organoplatinum Compounds; 0 / Pyrazines; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 69G8BD63PP / Bortezomib; U3P01618RT / Fluorouracil
  •  go-up   go-down


35. Levy MJ, Clain JE, Clayton A, Halling KC, Kipp BR, Rajan E, Roberts LR, Root RM, Sebo TJ, Topazian MD, Wang KK, Wiersema MJ, Gores GJ: Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc; 2007 Sep;66(3):483-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Malignancy was diagnosed in 30 of 42 patients, including esophageal squamous cell carcinoma, esophageal adenocarcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, pancreatic mucinous cystic neoplasia, intraductal papillary mucinous neoplasia, metastatic forearm sarcoma, small cell and non-small cell lung cancer, thyroid carcinoma, malignant GI stromal tumor, melanoma, adenocarcinoma of unknown primary, and lymphoma.


36. Hashim AR, Al-Quryni AM: Carcinoma of unknown primary site. Saudi Med J; 2005 Jan;26(1):47-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma of unknown primary site.
  • OBJECTIVE: To verify the spectrum of manifestations of carcinoma of unknown primary site, histopathological type and outcome, as well as to identify the prognostic factors for patient's outcome and their survival rate.
  • METHODS: From January 2001 to July 2002, in Basrah Teaching Hospital, Basrah, Iraq, 60 patients (27 males and 33 females), (mean age 58.8 +/- 11.1 years) who had fulfilled the criteria for carcinoma of unknown primary site were studied.
  • Adenocarcinoma was the most common histopathological type (63% of cases), while sequamous cell carcinoma was the least (13%).
  • Age > or = 60, smoking, adenocarcinoma type and multiple site of metastasis were bad prognostic factors for the outcome.
  • [MeSH-major] Neoplasms, Unknown Primary / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Carcinoma / mortality. Carcinoma, Squamous Cell / mortality. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Saudi Med J. 2005 Nov;26(11):1840-3 [16311687.001]
  • (PMID = 15756352.001).
  • [ISSN] 0379-5284
  • [Journal-full-title] Saudi medical journal
  • [ISO-abbreviation] Saudi Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


37. Afify A, Lynne LC, Howell L: Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions. Diagn Cytopathol; 2007 Feb;35(2):105-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant effusions included 18 cases of metastatic adenocarcinomas (9 ovarian, 3 breast, 3 pulmonary, 3 adenocarcinoma of unknown primary) and 2 cases of lymphomas.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230576.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


38. Choi GY, Kim A, Kim CN, Yoon SJ, Jung SH, Ko BS, Yang HY, John BM, Kim SH, Nam HJ, Go H: [A case of subphrenic abscess with ileal fistula caused by metastatic adenocarcinoma of unknown origin]. Korean J Gastroenterol; 2005 Dec;46(6):471-4
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of subphrenic abscess with ileal fistula caused by metastatic adenocarcinoma of unknown origin].
  • Reported cases of intestinal fistula caused by adenocarcinoma were complicated by direct invasion.
  • In this report, a 70-year-old male had a subphrenic abscess with intestinal fistula and the cause was a metastatic adenocarcinoma of unknown origin.
  • Invasion of the ileum by metastatic adenocarcinoma was diagnosed by the histologic examination of surgical specimen.
  • [MeSH-major] Adenocarcinoma / secondary. Ileal Diseases / etiology. Ileal Neoplasms / secondary. Intestinal Fistula / etiology. Neoplasms, Unknown Primary. Subphrenic Abscess / etiology

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16371722.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


39. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Matrix metalloproteinases in carcinoma of unknown primary. Cancer; 2005 Nov 15;104(10):2282-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinases in carcinoma of unknown primary.
  • BACKGROUND: The purpose was to study proteolysis-related molecules, matrix metalloproteinase-2 (MMP-2) and MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1), in carcinoma of unknown primary (CUP).
  • METHODS: Paraffin-embedded tumor material from 75 patients diagnosed with CUP was used.
  • Tumor histologies were adenocarcinoma (77%), undifferentiated carcinoma (19%), and squamous cell carcinoma (4%) and patients were categorized into favorable (62%) and unfavorable (38%) subsets.
  • CONCLUSIONS: MMP-2, MMP-9, and TIMP-1 are widely expressed in CUP, suggesting an essential role of proteolysis in these tumors.
  • TIMP-1 may be considered a possible marker of poor prognosis in CUP patients.
  • [MeSH-major] Carcinoma / enzymology. Carcinoma / secondary. Matrix Metalloproteinases / metabolism. Neoplasms, Unknown Primary / enzymology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society
  • (PMID = 16220559.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tissue Inhibitor of Metalloproteinases; EC 3.4.24.- / Matrix Metalloproteinases
  •  go-up   go-down


40. Caballero Gullón L, Borrego Dorado I, Vázquez Albertino R: [A colon adenocarcinoma and a pharyngeal carcinoma incidentally detected by means of (18)F-FDG PET in a patient diagnosed of lung cancer]. Rev Esp Med Nucl; 2010 Jan-Feb;29(1):29-31
MedlinePlus Health Information. consumer health - Throat Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A colon adenocarcinoma and a pharyngeal carcinoma incidentally detected by means of (18)F-FDG PET in a patient diagnosed of lung cancer].
  • [Transliterated title] Adenocarcinoma de colon y carcinoma faríngeo detectados incidentalmente mediante (18)F-FDG PET en paciente diagnosticado de cáncer de pulmón.
  • It is also especially useful in patients with solitary pulmonary nodule, bronchogenic carcinoma, head and neck cancer, colon cancer, tumors of unknown origin, lymphomas, etc.
  • Its capacity to detect previously unsuspected second or third primary tumors has also been demonstrated.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Lung Neoplasms / radiography. Neoplasms, Multiple Primary / radionuclide imaging. Pharyngeal Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier España, S.L. y SEMNIM. All rights reserved.
  • (PMID = 19969392.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Takemura T, Ogata N, Yumoto E: [Clinical analysis of cervical metastatis from an unknown primary carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2005 Oct;108(10):996-1003
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of cervical metastatis from an unknown primary carcinoma].
  • From 1997 to 2004, 19 cases-18 men and 1 woman-with cervical lymph node metastasis from an unknown primary carcinoma were retrospectively investigated regarding the clinical observation and the treatment outcome.
  • With respect to the histopathological types, 16 cases had squamous cell carcinoma, 2 cases had adenocarcinoma and 1 case had ductal carcinoma.
  • The presence of primary lesions was comfirmed in 11 cases (3 tonsil, 1 nasopharynx, 1 base of tongue, 2 hypopharynx, 1 esophagus, 1 larynx, 1 gallduct, 1 mammary gland) after the treatment of their metastatic leisions.
  • The 3-year survival rate of cases with known primary sites and cases with unknown primary sites after treatment were 55% and 83%, respectively.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Ductal / secondary. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285615.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


42. Shield PW, Koivurinne K: The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. Cytopathology; 2008 Aug;19(4):218-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To determine the value of calretinin and cytokeratin (CK) 5/6 in discriminating mesothelioma from adenocarcinoma in serous effusion specimens.
  • The adenocarcinomas included metastatic carcinomas from the breast (12), lung (19), stomach (3), colon (1), pancreas (2), ovary (6) endometrium (1) and 23 histologically confirmed metastases from unknown primary sites.
  • Only 3% (2/67) of adenocarcinomas were positive for calretinin, one being a lung adenocarcinoma and the other an adenocarcinoma of unknown primary site in an ascitic fluid.
  • Six (9%) adenocarcinomas were positive, including metastases from the lung (1), breast (1), ovary (2) and unknown primary site (2).
  • Four of the six adenocarcinoma cases positive for CK5/6 were in ascitic fluids.
  • Only one adenocarcinoma case, (which was from unknown primary site in an ascitic fluid sample), was positive for both markers.
  • The two markers make a useful addition to EMA and the panel of adenocarcinoma markers routinely applied to effusion specimens.

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17916095.001).
  • [ISSN] 1365-2303
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / Keratin-5; 0 / Keratin-6; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


43. Ueda J, Aimoto T, Nakamura Y, Hiroi M, Yamahatsu K, Hayakawa T, Naito Z, Uchida E: [Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma]. Nihon Shokakibyo Gakkai Zasshi; 2010 12;107(12):1941-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma of unknown primary associated with duodenal carcinoma].
  • Although as duodenal GIST was diagnosed, histologic examination for frozen sections during the procedure revealed tubular adenocarcinoma of the duodenum and pancreaticoduodenal lymph node metastasis of neuroendocrine carcinoma.
  • Clinicopathologically, the neuroendocrine carcinoma of the pancreaticoduodenal lymph node was considered to be metastasis from an unknown primary lesion.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Neuroendocrine / secondary. Duodenal Neoplasms / pathology. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139363.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


44. Møller AK, Gundgaard MG, Petersen BL, Daugaard G: [Unknown primary tumour--diagnostic strategies and treatment]. Ugeskr Laeger; 2008 Nov 24;170(48):3946-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unknown primary tumour--diagnostic strategies and treatment].
  • Unknown primary tumour (UPT) is defined as a histologically confirmed metastatic malignancy for which no primary site has been detected.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adenocarcinoma / therapy. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / therapy. Disease Progression. Female. Humans. Lymphatic Metastasis. Male. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087733.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Bender RA, Erlander MG: Molecular classification of unknown primary cancer. Semin Oncol; 2009 Feb;36(1):38-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification of unknown primary cancer.
  • The diagnosis of unknown primary carcinoma is often the result of the failure of light microscopy and immunohistochemistry to elucidate the origin of adenocarcinoma or poorly differentiated carcinoma.
  • Recent advances in gene expression profiling using either reverse transcription polymerase chain reaction (RT-PCR) or microarray have enabled researchers to develop expression profiles unique to a wide variety of well-characterized primary cancers and to compare these unique signatures with those from unknown primary cancers.
  • In fact, the overall accuracy of genomic cancer classification in patients with known primary cancers is 80% to 90%.
  • [MeSH-major] Neoplasms, Unknown Primary / classification. Neoplasms, Unknown Primary / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179186.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 26
  •  go-up   go-down


46. Wang ZP, Liu YT, Yang J: [Classification and regression tree analysis of 154 patients with cancer of unknown primary]. Zhonghua Zhong Liu Za Zhi; 2010 Sep;32(9):690-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Classification and regression tree analysis of 154 patients with cancer of unknown primary].
  • OBJECTIVE: To explore the prognostic factors and their impact on survival of patients with cancer of unknown primary (CUP).
  • METHODS: The clinical and follow up data of 154 CUP patients referred to the Cancer Hospital & Institute, Chinese Academy of Medical Sciences from January 1, 2003 to December 31, 2007 were analyzed.
  • RESULTS: The median survival for 154 eligible consecutive CUP patients was 18.2 months, and the 5-year survival rate was 1.3%.
  • The median survival of the 5 subsets ranged from 5.5 months (younger than 34 years old subgroup) to 61.8 months for patients at age of 34 to 60, with one or two organ sites involved, and non-adenocarcinoma histology subsets.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Neoplasms, Unknown Primary / classification

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122385.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


47. Pejcić I, Vrbić S, Filipović S, Sćekić M, Petković I, Pejcić L, Djenić N: [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site]. Vojnosanit Pregl; 2010 Sep;67(9):723-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of serum tumor markers monitoring metastases in carcinomas of unknown primary site].
  • BACKGROUND/AIM: Unknown primary tumors represent a heterogeneous group of malignancies that are indicative of ominous prognosis.
  • Cancer of unknown primary site (CUP) is defined as the lack of any detectable primary site after full evaluation, and accounts for approximately 3-5% of all newly diagnosed patients with malignancies.
  • On histological examination, all the patients were presented with metastatic tumors whose primary site (origin) could not be detected with noninvasive diagnostic techniques.
  • Following the routine light microscopy, all histological findings were classified into one of the following three groups: plano-cellular carcinoma--8 patients; adenocarcinoma--33 patients; unclassifiable (undifferentiated) carcinoma--22 patients.
  • CONCLUSION: Increased values of serum tumor markers are very often in CUP.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / blood. Carcinoma / secondary. Carcinoma, Squamous Cell / secondary. Neoplasms, Unknown Primary / pathology


48. Shibata H: [Treatment of cancer of unknown primary, today and future]. Gan To Kagaku Ryoho; 2009 Jun;36(6):918-22

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of cancer of unknown primary, today and future].
  • Cancer of unknown primary(CUP)is a malignant disease with metastases such as lymph nodes, lung or liver metastasis, and without an identified primary site.
  • CUP constitutes 5% of all human malignant diseases.
  • Chemotherapy based on the primary site is not applicable for the treatment of CUP.
  • It is very difficult to apply any regimens without information on the primary sites.
  • To resolve this problem, molecular diagnostic technologies using a gene expression profiling platform to identify the primary site of CUP are now applied.
  • Primary site-dependent chemotherapy could be conducted in accordance with the result of the molecular diagnosis of the primary site.
  • Identification of the underlying mechanism that is specific to the unfavorable CUP may be a clue to develop a novel treatment for CUP.
  • [MeSH-major] Neoplasms, Unknown Primary / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Female. Gene Expression Profiling. Humans. Lymphatic Metastasis. Male. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542712.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Nakagawa T, Hiraoka N, Ihara F, Komiyama M, Kanai Y, Matsuno Y: Primary adenocarcinoma of the rete testis with preceding diagnosis of pulmonary metastases. Int J Urol; 2006 Dec;13(12):1532-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of the rete testis with preceding diagnosis of pulmonary metastases.
  • We report a case of primary adenocarcinoma of the rete testis in a 55-year-old man with pulmonary metastases that were detected 11 months prior to the diagnosis of the primary lesion.
  • Primary adenocarcinoma of the rete testis is an extremely rare malignant tumor with a poor outcome.
  • The most common primary symptom is a scrotal mass, often accompanied by hydrocele and chronic epididymitis.
  • We cannot forget that rete testis is a possible primary site for a primary, unknown metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Rete Testis / pathology. Testicular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17118031.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


50. Park SY, Kim BH, Kim JH, Lee S, Kang GH: Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med; 2007 Oct;131(10):1561-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma.
  • CONTEXT: Although identification of the primary tumor in patients with metastatic adenocarcinoma has a profound clinical impact, diagnosing the organ of origin is frequently difficult.
  • Because none of the individual immunohistochemical markers used for tissue identification are both site specific and site sensitive, multiple markers are needed to improve the prediction of primary sites.
  • OBJECTIVE: To develop an effective approach to immunohistochemically evaluate metastatic adenocarcinoma for the assignment of a likely primary site of origin.
  • DESIGN: Expression profiles of CDX2, cytokeratin (CK) 7, CK20, thyroid transcription factor 1 (TTF-1), carcinoembryonic antigen (CEA), MUC2, MUC5AC, SMAD4, estrogen receptor (ER), and gross cystic disease fluid protein 15 (GCDFP-15) were generated in adenocarcinomas from 7 primary sites, followed by construction of a decision tree and design of multiple-marker panels.
  • Expression of these markers was evaluated immunohistochemically in 314 primary adenocarcinomas (50 cases each of colorectal, gastric, lung, pancreatic, bile duct, and breast, and 14 cases of ovarian origin) using the tissue array method.
  • Results were validated using 60 cases of metastatic adenocarcinoma with known primaries.
  • RESULTS: Organ-specific immunostaining profiles using multiple markers provided high sensitivity, specificity, and positive predictive value in detecting primary adenocarcinomas, as follows: colorectal, TTF-1-/CDX2+/CK7-/CK20+ or TTF-1-/CDX2+/CK7-/CK20-/(CEA+ or MUC2+); ovarian, CK7+/MUC5AC+/TTF-1-/CDX2-/CEA-/GCDFP-15-; breast, GCDFP-15+/TTF-1-/CDX2-/CK7+/CK20- or ER+/ TTF-1-/CDX2-/CK20-/CEA-/MUC5AC-; lung, TTF-1+ or TTF-1-/CDX2-/CK7+/CK20-/GCDFP-15-/ER-/CEA-/ MUC5AC-; pancreaticobiliary, TTF-1-/CDX2-/CK7+/ CEA+/MUC5AC+; and stomach, TTF-1-/CDX2+/CK7+/ CK20-.
  • CONCLUSIONS: Determination of tissue-specific immunostaining profiles is valuable in the diagnostic differentiation of metastatic adenocarcinomas from seven common primary sites and should help to correctly predict the organ of primary tumor origin.
  • [MeSH-major] Adenocarcinoma / chemistry. Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Neoplasm Proteins / analysis
  • [MeSH-minor] Decision Trees. Female. Humans. Neoplasms, Unknown Primary / chemistry. Neoplasms, Unknown Primary / diagnosis. Predictive Value of Tests. Sensitivity and Specificity. Tissue Array Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922593.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


51. Oien KA: Pathologic evaluation of unknown primary cancer. Semin Oncol; 2009 Feb;36(1):8-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathologic evaluation of unknown primary cancer.
  • The pathologic approach to metastases of unknown primary cancer (UPC) is stepwise and uses the clinical context, morphology, and, where necessary, immunohistochemistry (IHC).
  • Finally, for adenocarcinoma, the prediction of primary tumor site, including lung, pancreas, stomach, colon, ovary, prostate, and breast, is discussed.
  • [MeSH-major] Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179185.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 129
  •  go-up   go-down


52. Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer; 2007 Sep;43(14):2026-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Switching benchmarks in cancer of unknown primary: from autopsy to microarray.
  • INTRODUCTION: Cancer of unknown primary (CUP) is associated with unknown biology and dismal prognosis.
  • Information on the primary site of origin is scant and has never been analysed.
  • We systematically reviewed all published evidence on the CUP primary site identified by two different approaches, either autopsy or microarray gene expression profiling.
  • METHODS: Published reports on identification of CUP primary site by autopsy or microarray-based multigene expression platforms were retrieved and analysed for year of publication, primary site, patient age, gender, histology, rate of primary identification, manifestations and metastatic deposits, microarray chip technology, training and validation sets, mathematical modelling, classification accuracy and number of classifying genes.
  • RESULTS: From 1944 to 2000, a total of 884 CUP patients (66% males) underwent autopsy in 12 studies after presenting with metastatic or systemic symptoms and succumbing to their disease.
  • A primary was identified in 644 (73%) of them, mostly in the lung (27%), pancreas (24%), hepatobiliary tree (8%), kidneys (8%), bowel, genital system and stomach, as a small focus of adenocarcinoma or poorly differentiated carcinoma.
  • Four studies using microarray technology profiled more than 500 CUP cases using classifier set of genes (ranging from 10 to 495) and reported strikingly dissimilar frequencies of assigned primary sites (lung 11.5%, pancreas 12.5%, bowel 12%, breast 15%, hepatobiliary tree 8%, kidneys 6%, genital system 9%, bladder 5%) in 75-90% of the cases.
  • CONCLUSIONS: Evolution in medical imaging technology, diet and lifestyle habits probably account for changing epidemiology of CUP primaries in autopsies.
  • Discrepant assignment of primary sites by microarrays may be due to the presence of 'sanctuary sites' in autopsies, molecular misclassification and the postulated presence of a pro-metastatic genetic signature.
  • In view of the absence of patient therapeutic or prognostic benefit with primary identification, gene expression profiling should be re-orientated towards unraveling the complex pathophysiology of metastases.
  • [MeSH-major] Microarray Analysis / methods. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17698346.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


53. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G: Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol; 2010 Oct;17(10):2728-32

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel adenocarcinoma: understaged and undertreated?
  • BACKGROUND: Primary small bowel adenocarcinoma (SBA) is a rare, chemoresistant tumor with an aggressive clinical nature.
  • Surgery is the mainstay of therapy, but the extent of lymph node (LN) recovery necessary for optimal care of jejunoileal SBA is unknown.
  • MATERIALS AND METHODS: The SEER database was queried to identify patients whose primary jejunoileal SBA was diagnosed between 1995 and 2005.
  • RESULTS: Of 1444 patients with primary SBA, 93 (6.4%), 529 (36.6%), 356 (24.7%), and 466 (32.3%) were initially diagnosed with stage I, II, III, and IV disease, respectively.
  • Multivariate analysis identified age, AJCC stage, site of primary tumor, recovery of ≥10 LNs, and number of positive nodes as significant for OS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20458546.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Kolesnikov-Gauthier H, Levy E, Merlet P, Kirova J, Syrota A, Carpentier P, Meignan M, Piedbois P: FDG PET in patients with cancer of an unknown primary. Nucl Med Commun; 2005 Dec;26(12):1059-66

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG PET in patients with cancer of an unknown primary.
  • BACKGROUND: This prospective study was undertaken to address the capacity of positron emission tomography (PET) with 2-[18F]fluoro-2-deoxy-D-glucose (18F-FDG) to determine the primary tumour site of carcinomas with unknown primary site.
  • PATIENTS AND METHODS: Twenty-five patients with metastases from adenocarcinoma or undifferentiated carcinoma of unknown primary site (CUP) were included prospectively.
  • For all patients, extensive imaging was unsuccessful in localizing the primary site.
  • All hot spots that could not be attributed to a metastatic site were considered as the primary tumour.
  • In six patients, FDG PET showed a primary tumour site which was confirmed by follow-up or surgery.
  • In five patients, the primary tumour site was suggested by FDG PET but not confirmed by clinical outcome.
  • No primary tumour was found in the other patients, with a mean follow-up of 15 months.
  • CONCLUSION: In our series, FDG PET allowed the identification of primary tumour site in one quarter of patients with CUP (6/24).
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / diagnosis. Neoplasms / radionuclide imaging. Neoplasms, Unknown Primary / diagnosis. Positron-Emission Tomography / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. False Positive Reactions. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Whole-Body Counting

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16264351.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


55. Dockery KF, Puri S, Qazi R, Davis D: FDG-PET on the trail of an unsuspected primary malignancy in the breast. Clin Nucl Med; 2008 Mar;33(3):175-80
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET on the trail of an unsuspected primary malignancy in the breast.
  • Proper identification of the primary malignancy can radically alter clinical management for the patient's benefit.
  • This is a report of an unsuspected primary breast cancer in a patient being worked up for presumptive lymphoma.
  • Prior investigation of lymphedema in the left lower extremity found widespread lymphadenopathy on computed tomography imaging, leading to initial biopsy revealing adenocarcinoma of unknown primary.
  • F-18 fluorodeoxyglucose PET/computed tomography altered management by localizing an F-18 fluorodeoxyglucose avid breast nodule, directing breast biopsy with specific immunohistochemical analysis for breast cancer lineage in metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Breast Neoplasms / radiography. Fluorodeoxyglucose F18. Positron-Emission Tomography. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18287839.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. Miwa K, Fujioka S, Adachi Y, Haruki T, Taniguchi Y, Nakamura H: Mediastinal lymph node carcinoma of an unknown primary site: clinicopathological examination. Gen Thorac Cardiovasc Surg; 2009 May;57(5):239-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal lymph node carcinoma of an unknown primary site: clinicopathological examination.
  • PURPOSE: We examined the clinicopathological features of four mediastinal lymph node carcinomas from an unknown primary site.
  • METHODS: Four patients with mediastinal lymph node carcinoma from an unknown primary site were treated at our hospital during the past 6 years.
  • Histologically, one lesion was poorly differentiated adenocarcinoma, two were poorly differentiated squamous cell carcinoma, and one was undifferentiated carcinoma.
  • CONCLUSION: Radical resection of mediastinal lymph node carcinoma with an unknown primary site has the possibility of a good prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Mediastinal Neoplasms / secondary. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Med J. 1979 Jun 9;1(6177):1530-3 [466103.001]
  • [Cites] Cancer. 1970 Oct;26(4):816-20 [5506606.001]
  • [Cites] J Surg Oncol. 1983 Jun;23(2):73-6 [6855244.001]
  • [Cites] Ann Surg. 1977 Nov;186(5):625-30 [921356.001]
  • (PMID = 19440819.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


57. Fernández Cotarelo MJ, Guerra Vales JM: [Diagnostic approach to cancer of unknown primary site]. Rev Clin Esp; 2009 Jul-Aug;209(7):347-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic approach to cancer of unknown primary site].
  • Cancer of unknown primary site (CUPS) is a heterogeneous entity defined by the presence of a histologically-proven metastatic neoplasm, in which the original tumor cannot be identified after a targeted study.
  • The current guidelines for CUPS focus is not based on the search for the primary neoplasm but rather on the identification of patients who may benefit from a treatment that will prolong their survival, based on the clinical and histological characteristics of each case.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Biomarkers, Tumor / blood. Carcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Neuroendocrine Tumors / diagnosis. Ovarian Neoplasms / diagnosis. Positron-Emission Tomography. Practice Guidelines as Topic. Prostatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19709540.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


58. Pentheroudakis G, Briasoulis E, Karavassilis V, Fountzilas G, Xeros N, Samelis G, Samantas E, Pavlidis N: Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective? Acta Oncol; 2005;44(2):155-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy for patients with two favourable subsets of unknown primary carcinoma: active, but how effective?
  • Carcinoma of unknown primary (CUP) is characterized by dismal patient survival.
  • The outcome of patients with two favourable risk CUP subsets was studied.
  • The majority had poorly differentiated adenocarcinoma or undifferentiated carcinoma, treated with platinum-taxane based chemotherapy from 1996 till 2002.
  • Modern combination chemotherapy has satisfactory activity, with a minority of CUP patients enjoying long-term responses.
  • [MeSH-major] Adenocarcinoma / drug therapy. Carcinoma / drug therapy. Neoplasms, Unknown Primary / drug therapy. Peritoneal Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15788295.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Bridged Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


59. Molina Garrido MJ, Guillén Ponce C, Maciá Escalante S, Pons Sanz V, Carrato Mena A: Cushing's paraneoplastic syndrome as first manifestation of an adenocarcinoma of unknown origin. Clin Transl Oncol; 2006 Aug;8(8):621-3
Genetic Alliance. consumer health - Cushing's Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's paraneoplastic syndrome as first manifestation of an adenocarcinoma of unknown origin.
  • We hereby present the case of a patient diagnosed with a metastatic carcinoma of unknown origin associated with two paraneoplastic syndromes: a Cushing's syndrome and a sensitive-motor axonal neuropathy, a very uncommon association.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Adenocarcinoma / diagnosis. Neoplasms, Unknown Primary / diagnosis. Paraneoplastic Polyneuropathy / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1990 Jul;50(1):52-7 [2164362.001]
  • [Cites] Cancer. 1992 Jan 1;69(1):66-71 [1309310.001]
  • [Cites] Rev Mal Respir. 1999 Jun;16(3):395-7 [10472651.001]
  • [Cites] Eur J Endocrinol. 2001 Jan;144(1):81 [11174841.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5593-602 [14671138.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):157-64 [7799015.001]
  • [Cites] An Sist Sanit Navar. 2005 May-Aug;28(2):213-26 [16155618.001]
  • [Cites] Clin Endocrinol (Oxf). 1990 Mar;32(3):275-81 [2160871.001]
  • [Cites] Intern Med. 2003 Sep;42(9):831-3 [14518671.001]
  • [Cites] N Engl J Med. 2000 Feb 10;342(6):414-20 [10666433.001]
  • [Cites] Endocrinol Metab Clin North Am. 1994 Sep;23 (3):511-37 [7805651.001]
  • [Cites] Acta Radiol. 1999 Jan;40(1):100-3 [9973912.001]
  • (PMID = 16952854.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


60. Peter S, Eltoum I, Eloubeidi MA: EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy. Gastrointest Endosc; 2009 Dec;70(6):1266-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EUS-guided FNA of peritoneal carcinomatosis in patients with unknown primary malignancy.
  • OBJECTIVE: We aimed to determine the feasibility and success in sampling lesions in the peritoneum suspicious for carcinomatosis without a primary source.
  • Two patients had metastatic adenocarcinoma, 1 patient had lymphoma, and 1 patient had metastatic breast carcinoma.
  • In the setting of an unknown primary cancer, EUS-guided FNA facilitates acquisition of tissues for treatment allocation, thus avoiding the need for laparoscopy or laparotomy.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Carcinoma / pathology. Endosonography. Neoplasms, Unknown Primary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gastrointest Endosc. 2011 Jan;73(1):188-9 [21184887.001]
  • (PMID = 19640520.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Miura K, Yoshizawa K, Tamaki M, Okumura K, Furukita Y: [Mediastinal lymph node carcinoma of unknown primary site; report of a case]. Kyobu Geka; 2009 Mar;62(3):255-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal lymph node carcinoma of unknown primary site; report of a case].
  • No preoperative examination could detect the primary lesion.
  • Histological examination revealed poorly differentiated adenocarcinoma.
  • She was diagonosed as metastatic mediastinal lymph node carcinoma of unknown primary site.
  • Good results may be obtained by multimodality therapies for cancer in mediastinal lymph node of unknown primary site.
  • [MeSH-major] Adenocarcinoma / secondary. Lymph Nodes / pathology. Mediastinal Neoplasms / secondary. Neoplasms, Unknown Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280962.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


62. Hu M, Li MH, Kong L, Liu NB, Yang GR, Yu JM: [(18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):699-701
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [(18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin].
  • OBJECTIVE: To evaluate the value of (18)F-FDG PET-CT in detecting the primary tumor in patients with metastatic cancers of unknown primary origin.
  • METHODS: Sixty-seven patients with metastatic cancers of unknown primary origin after extensive conventional diagnostic work-up were enrolled into this study. (18)F-FDG PET-CT scans were performed at approximately 60 minutes after the intravenous injection of 7.4 MBq (18)F-FDG/kg, then delayed imaging scans was done at approximately 180 minutes for detecting the primary focus.
  • The correlation between (18)F-FDG PET-CT results and histopathological and clinical findings were analyzed, and the SUV of detected primary focus and that of metastatic cancers were compared.
  • RESULTS: Of the 67 patients, the primary tumors were identified in 39 (53.7%) by (18)F-FDG PET-CT, and 36 of them were confirmed by pathology or follow-up.
  • The SUV of metastatic tumors was significantly lower than that of primary tumors (t = 3.470,P = 0.001) and closely correlated with that of the primary tumors (r = 0.738, P = 0.000).
  • CONCLUSION: (18)F-FDG PET-CT is not only valuable in identifying the unknown primary tumor in patients with metastatic carcinoma, but can also be used to reveal the biological characteristics of the tumors by functional imaging.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Neoplasms, Unknown Primary / radionuclide imaging. Ovarian Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Female. Follow-Up Studies. Humans. Male. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173915.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


63. Pouessel D, Thezenas S, Culine S, Becht C, Senesse P, Ychou M: Hepatic metastases from carcinomas of unknown primary site. Gastroenterol Clin Biol; 2005 Dec;29(12):1224-32
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases from carcinomas of unknown primary site.
  • AIM: Hepatic metastases are often present at diagnosis of carcinoma of unknown primary site (CUP).
  • METHODS: One hundred and eighteen patients were treated at the Cancer Center of Montpellier from 1993 to 2002 for CUP initially metastatic to the liver.
  • RESULTS: The most frequent histological types observed were adenocarcinoma, undifferentiated, neuroendocrine and squamous-cell carcinomas.
  • CONCLUSIONS: According to this study, pretreatment evaluations, which were very extensive in some patients, were insufficient to identify the primary site of liver metastases.
  • [MeSH-major] Liver Neoplasms / mortality. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518276.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


64. Lucić SM, Lucić MA, Peter A, Jovanović D, Vucaj-Cirilović V: [Positron emission tomography/computed tomography in patients with cancer of unknown primary origin]. Acta Chir Iugosl; 2009;56(4):159-64
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Positron emission tomography/computed tomography in patients with cancer of unknown primary origin].
  • Cancer of unknown primary origin is not an uncommon clinical state, usually accounting for 2%-7% of all cancer patients.
  • MATERIAL AND METHODS: Positron emission tomography and computed tomography (PET/CT) was performed in 17 patients with histologically proven metastatic tumors of unknown primary and negative or inconclusive conventional diagnostic procedures.
  • PET / CT has pointed out the probable localization of primary tumors in 10 patients.
  • According histological diagnosis of carcinoma of unknown origin, most common is adenocarcinoma (64.71%).
  • Origin of the primary cancer was found in 72.73% patients with adenocarcinoma 66.67% of respondents with squamocelular carcinoma and 50% of respondents with low differentiated carcinoma.
  • Location of primary cancer was not found in 41.18% of the respondents, including patients with mucinous adenocarcinoma and patients with melanoma.
  • CONCLUSION: FDG PET/CT demonstrates very good whole-body imaging method in evaluation of patients with unknown primary carcinoma.
  • [MeSH-major] Neoplasms, Unknown Primary / radiography. Neoplasms, Unknown Primary / radionuclide imaging. Positron-Emission Tomography. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20420014.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


65. Wu Y, Yao LQ, Cheng J, Tian H: [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 May;30(5):1069-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site].
  • OBJECTIVE: To explore the diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site.
  • METHODS: Thirty-eight cases of metastatic bone marrow tumors were diagnosed by light microscopy, and the bone marrow samples from these cases with unknown primary tumor sites were examined by immunohistochemistry.
  • Immunohistochemistry identified the primary tumor sites in these cases, including 12 stomach cancers, 10 breast cancers, 8 prostate cancers, 4 lung cancers, 1 dorsal melanoma, 1 left foot melanoma, and 2 nasopharyngeal cancers.
  • CONCLUSION: Proper immunohistochemistry can help determine the primary tumor sites in patients with metastatic bone marrow tumor with unknown primary tumor sites.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Marrow Examination / methods. Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501396.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


66. Ohtsubo K, Watanabe H, Yamada T, Tsuchiyama T, Mouri H, Yamashita K, Yasumoto K, Ikeda H, Nakanuma Y, Yano S: Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy. Intern Med; 2009;48(18):1651-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.
  • We report a 47-year-old man with cancer of unknown primary site in whom pancreatic cancer was confirmed at autopsy.
  • Although a primary lesion was not confirmed, we planned to perform tumor marker-oriented chemotherapy because pancreatic cancer was suspected as the primary lesion based on tumor markers and pathological findings from metastatic lymph node.
  • Microscopic examination at autopsy revealed poorly differentiated adenocarcinoma in the pancreatic head, although a pancreatic mass was not clear macroscopically.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / drug therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Autopsy. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755768.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DU-PAN-2 antigen, human; 0 / pancreatic associated antigen, SPan-1; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


67. Lequin D, Fizazi K, Toujani S, Souquère S, Mathieu MC, Hainaut P, Bernheim A, Praz F, Busson P: Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary). BMC Cancer; 2007;7:225
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological characterization of two xenografts derived from human CUPs (carcinomas of unknown primary).
  • BACKGROUND: Carcinomas of unknown primary site (CUP) are epithelial malignancies revealed by metastatic lesions in the absence of any detectable primary tumor.
  • METHODS: We attempted xenografts of CUP clinical specimens in immunodeficient mice and subsequent in vitro culture of transplanted malignant cells.
  • Distinct rare missense mutations of the TP53 gene were detected in Capi1 (codon 312) and Capi3 (codon 181); the codon 181 mutation is consistent with a previously reported similar finding in a small series of CUP specimens.
  • CONCLUSION: Our data suggest that xenografted tumors can be obtained from a substantial fraction of CUP clinical specimens.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / secondary. Gene Expression Regulation, Neoplastic. Neoplasm Transplantation / pathology. Neoplasms, Unknown Primary / genetics. Neoplasms, Unknown Primary / pathology. Transplantation, Heterologous / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2007 Oct 8;97(7):857-61 [17876336.001]
  • [Cites] Eur J Cancer. 2007 Sep;43(14):2026-36 [17698346.001]
  • [Cites] Int J Cancer. 2002 Jan 10;97(2):186-94 [11774263.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Hum Mutat. 2002 Jun;19(6):607-14 [12007217.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):23-31 [12659667.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3479-82 [12972523.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):297-301 [15015611.001]
  • [Cites] Anticancer Res. 1993 Sep-Oct;13(5A):1619-23 [8239543.001]
  • [Cites] Mol Cell Biol. 1996 Sep;16(9):4952-60 [8756654.001]
  • [Cites] Diagn Mol Pathol. 1998 Oct;7(5):260-6 [9990484.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4765-9 [10519380.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Mol Cancer Res. 2005 Mar;3(3):119-29 [15798092.001]
  • [Cites] Clin Chem. 2005 Jul;51(7):1284-7 [15976115.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):139-48 [17210693.001]
  • [Cites] J Clin Oncol. 2007 Mar 1;25(7):884-96 [17327610.001]
  • [Cites] Oncologist. 2007 Apr;12(4):418-25 [17470684.001]
  • [Cites] Hum Mutat. 2007 Jun;28(6):622-9 [17311302.001]
  • [Cites] Cancer Treat Rev. 2007 Jun;33(4):391-406 [17368733.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • (PMID = 18088404.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  • [Other-IDs] NLM/ PMC2241840
  •  go-up   go-down


68. Parvez T, Ibraheim MI: Diagnostic and prognostic yield of tumor markers in cancer of unknown primary site. J Coll Physicians Surg Pak; 2006 Feb;16(2):154-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and prognostic yield of tumor markers in cancer of unknown primary site.
  • A case of metastatic carcinoma of unknown primary is reported that had widely disseminated disease from the very outset.
  • Every effort was made to find out the primary by integrating all results and specially tumor markers.
  • It was assumed that lung was the most possible site for primary.
  • [MeSH-major] Adenocarcinoma / secondary. Biomarkers, Tumor / blood. Bone Neoplasms / secondary. CA-125 Antigen / blood. Lung Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499817.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


69. Kawasaki K, Kamigaki T, Takase S, Maki K, Tamura T, Shirasaka D, Shinoda H, Nakamura T, Kuroda D, Kuroda Y: [A case of unknown primary cancer responding to TS-1]. Gan To Kagaku Ryoho; 2006 Aug;33(8):1125-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of unknown primary cancer responding to TS-1].
  • Although many different examinations were performed to detect primary cancer, none was found.
  • We diagnosed unknown primary cancer (UPC), and administered TS-1 (100 mg/day).
  • An intra-abdominal LN biopsy was performed, and an adenocarcinoma was seen at a lymph vessel.
  • Autopsy was not performed, and primary cancer was not seen till the end.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Lymph Nodes / pathology. Neoplasms, Unknown Primary / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16912532.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


70. Ishiguro T, Fu Y, Sadatou T, Shimokawa N, Shibamoto K: [Detection of unknown primary tumor in a patient with cerebellar metastasis using FDG PET-CT: case report]. No Shinkei Geka; 2006 Oct;34(10):1027-32
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of unknown primary tumor in a patient with cerebellar metastasis using FDG PET-CT: case report].
  • Identification of unknown primary tumors in patients with brain metastasis is a continued diagnostic challenge.
  • We report a case to show that FDG PET-CT was able to detect an unknown primary tumor.
  • The histological diagnosis was adenocarcinoma metastasis.
  • In conclusion, from now on, FDG PET-CT will be considered as the first diagnostic process for patients presenting brain metastasis with an unknown primary tumor.
  • [MeSH-major] Cerebellar Neoplasms / secondary. Neoplasms, Unknown Primary / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052015.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK: The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol; 2010 Dec 25;118(6):441-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas.
  • Napsin-A, which is expressed in lung tissue, is a relatively new marker for lung adenocarcinoma.
  • In this study, the authors examined the utility of napsin-A compared with TTF-1 in cytologic specimens of primary and metastatic, poorly differentiated lung adenocarcinomas.
  • METHODS: The archives of the Department of Pathology at The Johns Hopkins Hospital were searched for cytologic cases of poorly differentiated lung adenocarcinoma that were histologically confirmed.
  • Tissue microarrays of lung adenocarcinoma also were examined.
  • CONCLUSIONS: Although TTF-1 had a higher sensitivity, napsin-A was useful as a surrogate marker when encountering a poorly differentiated lung adenocarcinoma or an unknown primary tumor, particularly in cytologic specimens and difficult cases.
  • [MeSH-major] Adenocarcinoma / diagnosis. Aspartic Acid Endopeptidases / analysis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Nuclear Proteins / analysis. Transcription Factors / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20830690.001).
  • [ISSN] 1934-662X
  • [Journal-full-title] Cancer cytopathology
  • [ISO-abbreviation] Cancer Cytopathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; EC 3.4.23.- / Aspartic Acid Endopeptidases; EC 3.4.23.- / NAPSA protein, human
  •  go-up   go-down


72. Huang Y, Peters CJ, Fitzgerald RC, Gjerset RA: Progressive silencing of p14ARF in oesophageal adenocarcinoma. J Cell Mol Med; 2009 Feb;13(2):398-409
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive silencing of p14ARF in oesophageal adenocarcinoma.
  • The frequency of oesophageal adenocarcinoma is increasing in Western countries for unknown reasons, and correlates with a corresponding increase in the pre-malignant condition, Barrett's Oesophagus, which raises the risk of adenocarcinoma by some 40- to 125-fold.
  • We have used quantitative PCR, RT-PCR, methylation-specific PCR and chromatin-immunoprecipitation to examine the regulation and function of ARF in oesophageal adenocarcinoma tissue specimens and cell lines.
  • We find highly significant reductions (P< 0.001) in ARF expression during disease progression from normal oesophageal epithelium to Barrett's Oesophagus to adenocarcinoma, with 57/76 (75%) adenocarcinomas displaying undetectable levels of ARF expression.
  • Retention of ARF expression in adenocarcinoma is a highly significant indicator of increased survival (P< 0.001) and outperforms all clinical variables in a multivariate model.
  • CpG methylation as well as histone H3 methylation of lysines 9 and 27 contribute independently to ARF gene silencing in adenocarcinoma cell lines and can be reversed by 5-aza-2'-deoxycytidine.
  • The results suggest that silencing of ARF is involved in the pathogenesis of oesophageal adenocarcinoma and show that either DNA or histone methylation can provide the primary mechanism for ARF gene silencing.
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Gene Silencing. Tumor Suppressor Protein p14ARF

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2004 Jun 10;23(27):4780-8 [15107828.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):135-41 [15185075.001]
  • [Cites] Cancer Res. 2004 Oct 1;64(19):6867-73 [15466175.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Science. 1994 Apr 15;264(5157):436-40 [8153634.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Leukemia. 1997 Jan;11(1):1-5 [9001409.001]
  • [Cites] Br J Cancer. 1997;75(2):258-63 [9010035.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • [Cites] Cell. 1998 Mar 20;92(6):713-23 [9529248.001]
  • [Cites] Cell. 1998 Mar 20;92(6):725-34 [9529249.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jul 7;95(14):8292-7 [9653180.001]
  • [Cites] Cancer Res. 1998 Sep 1;58(17):3926-31 [9731504.001]
  • [Cites] Genes Dev. 1998 Oct 1;12(19):2984-91 [9765200.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6457-73 [9774662.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Dis Esophagus. 2006;19(1):10-4 [16364037.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Med Sci (Paris). 2006 May;22(5):519-24 [16687121.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5582-91 [16740693.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(10):1637-41 [16600663.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2005;70:129-37 [16869746.001]
  • [Cites] Nat Genet. 2006 Dec;38(12):1386-96 [17099711.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):232-6 [17200670.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7996-8001 [17804709.001]
  • [Cites] J Nutr. 2007 Dec;137(12):2622-8 [18029474.001]
  • [Cites] Oncogene. 1999 Oct 21;18(43):5843-9 [10557071.001]
  • [Cites] Cancer Res. 2000 Jan 1;60(1):129-33 [10646864.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3153-8 [10955797.001]
  • [Cites] Genes Dev. 2000 Sep 15;14(18):2358-65 [10995391.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):2057-64 [11062168.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2816-21 [11306450.001]
  • [Cites] Oral Oncol. 2001 Jun;37(4):341-4 [11337265.001]
  • [Cites] Oncogene. 2001 Aug 16;20(36):5025-32 [11526487.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Nov 9;288(4):921-6 [11688997.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Virchows Arch. 2002 Aug;441(2):133-42 [12189502.001]
  • [Cites] Cancer Gene Ther. 2002 Oct;9(10):830-9 [12224024.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6456-61 [12438235.001]
  • [Cites] Pathol Res Pract. 2002;198(12):785-94 [12608655.001]
  • [Cites] Int J Cancer. 2003 May 20;105(1):98-100 [12672037.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):683-9 [12753151.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • (PMID = 18410530.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA111868-02; United States / NCI NIH HHS / CA / R01 CA111868-03; United Kingdom / Medical Research Council / / MC/ U105365007; United States / NCI NIH HHS / CA / R01 CA111868-01; United States / NCI NIH HHS / CA / CA 111868; United Kingdom / Medical Research Council / / ; United States / NCI NIH HHS / CA / R01 CA111868-04; United States / NCI NIH HHS / CA / R01 CA111868-05; United States / NCI NIH HHS / CA / R01 CA111868; United States / NCI NIH HHS / CA / R01 CA111868-06
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Histones; 0 / Tumor Suppressor Protein p14ARF; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  • [Other-IDs] NLM/ NIHMS289834; NLM/ PMC3098888
  •  go-up   go-down


73. Kaya AO, Coskun U, Unlu M, Akdemir UO, Ozdemir NY, Zengin N, Benekli M, Yildiz R, Yaman E, Ozturk B, Gumus M, Uner A, Yamac D, Ucgul E, Buyukberber S: Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin. Asian Pac J Cancer Prev; 2008 Oct-Dec;9(4):683-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin.
  • PURPOSE: The aim of this study was to evaluate the role of whole body 18F-FDG PET/CT imaging in the detection of primary tumors in patients with a metastatic cancer from an unknown primary site.
  • According to the final pathologic diagnoses, rate of detection of the primary tumor site was determined.
  • RESULTS: A primary tumor site was shown by 18F-FDG PET/CT in 24 patients (24/43; 55.8%).
  • In a patient with an adenocarcinoma metastasis 18F-FDG PET/CT was falsely positive for an inflammatory lesion in the lung.
  • CONCLUSION: Whole body 18F-FDG PET/CT imaging has a high rate of detection of a primary tumor in patients with a carcinoma of unknown origin.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms, Unknown Primary / diagnostic imaging. Neoplasms, Unknown Primary / mortality. Positron-Emission Tomography / methods
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Adult. Aged. Breast Neoplasms / diagnostic imaging. Breast Neoplasms / mortality. Breast Neoplasms / secondary. Cause of Death. Cohort Studies. Confidence Intervals. Female. Humans. Kaplan-Meier Estimate. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Statistics, Nonparametric. Stomach Neoplasms / diagnostic imaging. Stomach Neoplasms / mortality. Stomach Neoplasms / secondary. Survival Analysis. Tomography, X-Ray Computed / methods. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19256759.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


74. Pentheroudakis G, Lazaridis G, Pavlidis N: Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence. Breast Cancer Res Treat; 2010 Jan;119(1):1-11
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary nodal metastases from carcinoma of unknown primary (CUPAx): a systematic review of published evidence.
  • Axillary lymph node metastases from adeno carcinoma or poorly differentiated carcinoma of unknown primary (CUPAx) represent a rare clinical entity without consensus on its biology, management and outcome.
  • CUPAx affected women at a mean age of 52 years, 66% of whom post-menopausal harbouring low-volume (N1, 48%) or high-volume (52%) nodal disease from ductal adenocarcinoma (83%).
  • Among a total of 446 patients managed with mastectomy, a small breast primary was identified histologically in 321 (72% of cases).
  • CUPAx patients were managed with axillary lymph node dissection coupled to mastectomy (59%), primary breast irradiation (26%) or observation (15%).
  • [MeSH-major] Adenocarcinoma / pathology. Axilla / pathology. Carcinoma / pathology. Lymphatic Metastasis / diagnosis. Neoplasms, Unknown Primary / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19771506.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 46
  •  go-up   go-down


75. Gupta K, Nada R, Das A, Kumar MS: Membranoproliferative glomerulonephritis in a carcinoma with unknown primary: an autopsy study. Indian J Pathol Microbiol; 2008 Apr-Jun;51(2):230-3
Genetic Alliance. consumer health - Glomerulonephritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membranoproliferative glomerulonephritis in a carcinoma with unknown primary: an autopsy study.
  • We report a rare autopsy case of a patient with metastatic carcinoma (with unknown primary) associated with MPGN.
  • The association between MPGN and metastatic carcinoma with unknown primary is uncommon and has not been previously reported in the literature.
  • [MeSH-major] Glomerulonephritis, Membranoproliferative / etiology. Neoplasms, Unknown Primary / complications
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Humans. Male. Splenic Neoplasms / complications. Splenic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603690.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


76. Schuette K, Folprecht G, Kretzschmar A, Link H, Koehne CH, Gruenwald V, Stahl M, Huebner G: Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary. Onkologie; 2009 Apr;32(4):162-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
  • BACKGROUND: Carcinomas of unknown primary (CUP) account for approximately 2-5% of all cancer diagnoses.
  • We performed a phase II study with oxaliplatin (OX) and capecitabine (CAP) as first-line treatment for patients with histo-or cytologically proven adeno- or undifferentiated CUP.
  • The primary endpoint was the response rate (RR).
  • RESULTS: 51 patients with CUP (71% with poorly differentiated adenocarcinoma; 41% ECOG performance status (PS) 0, 39% PS 1, 10% PS 2, 55% with elevated lactate dehydrogenase (LDH), and 39% with liver metastases) were enrolled in this study.
  • CONCLUSION: CAP/OX did not reach higher RR compared to a standard regimen with paclitaxel/carboplatin, which discourages further investigation of this schedule in CUP.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives. Neoplasms, Unknown Primary / drug therapy. Organoplatinum Compounds / administration & dosage

  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • [CommentIn] Onkologie. 2009 Apr;32(4):159-60 [19372709.001]
  • (PMID = 19372710.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


77. Yakushiji S, Ando M, Yonemori K, Kohno T, Shimizu C, Katsumata N, Fujiwara Y: Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan. Int J Clin Oncol; 2006 Dec;11(6):421-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of unknown primary site: review of consecutive cases at the National Cancer Center Hospital of Japan.
  • BACKGROUND: Cancer of unknown primary (CUP) is not a rare clinical entity, accounting for 3%-5% of all solid malignancies.
  • METHODS: We retrospectively reviewed 86 (38 male/48 female) patients with a diagnosis of CUP (exclusive of female patients with adenocarcinoma involving the axillary lymph nodes alone and patients with squamous cell carcinoma of the cervical lymph nodes) who were referred to the National Cancer Center Hospital between April 1996 and October 2002.
  • The histological diagnosis was adenocarcinoma in 61 patients (71%), poorly differentiated carcinoma in 18 patients (21%), and squamous cell carcinoma in 4 patients (5%).
  • Twenty-three female patients had peritoneal carcinomatosis of adenocarcinoma.
  • Sixty-one of the 86 patients (71%) were categorized as a subgroup of CUP without a specific therapy, and 55 of these 61 patients (90%) received platinum-containing regimens.
  • CONCLUSION: In this series, the survival of the patients in the CUP subgroup without a specific therapy did not seem worse than that in previous reports.
  • Empirical chemotherapy with platinum-containing regimens may benefit some CUP patients in a subgroup without a specific chemotherapy.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2003 Feb;8(1):23-5 [12601538.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Cancer. 1981 Jun 15;47(12):2923-7 [7260879.001]
  • [Cites] Ann Oncol. 1991 Jul;2(7):519-20 [1911461.001]
  • [Cites] Am J Clin Oncol. 2000 Dec;23(6):614-6 [11202809.001]
  • [Cites] Radiology. 1980 Feb;134(2):367-9 [7352215.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3479-82 [12972523.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):9-16 [14695313.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):364-71 [2841895.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1651-6 [11896116.001]
  • [Cites] Ann Oncol. 2000 Feb;11(2):211-5 [10761758.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2655-60 [11135228.001]
  • [Cites] Oncology. 1998 Mar-Apr;55(2):116-21 [9499185.001]
  • [Cites] Cancer. 2001 Feb 1;91(3):592-7 [11169943.001]
  • [Cites] JAMA. 1979 Jan 26;241(4):381-3 [758556.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2376-80 [9649162.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1810-2 [12175699.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] Ann Intern Med. 1981 Feb;94(2):181-6 [6162409.001]
  • [Cites] Ann Intern Med. 1989 Aug 1;111(3):213-7 [2502058.001]
  • (PMID = 17180509.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


78. Azoulay S, Adem C, Pelletier FL, Barete S, Francès C, Capron F: Skin metastases from unknown origin: role of immunohistochemistry in the evaluation of cutaneous metastases of carcinoma of unknown origin. J Cutan Pathol; 2005 Sep;32(8):561-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin metastases from unknown origin: role of immunohistochemistry in the evaluation of cutaneous metastases of carcinoma of unknown origin.
  • Determining the primary origin of skin metastases might be a challenging issue for pathologists, especially when there is no primary history or when this history is unavailable.
  • We have tried to assess the primary origin based on morphological data alone, and then using 13 antibodies (cytokeratins (CK) 5/6, 7, 19, 20, thyroid transcription factor-1, carcinoembryonic antigen, PS100, tumor-associated glycoprotein 72, BerEP4, estrogen receptor (ER), progesterone receptor (PR), CD10, and E-cadherin).
  • CK 20, ER, and PR were the most helpful markers to determine the primary origin of skin metastases by highlighting colorectal origin and mammary origin, respectively.
  • Skin metastases from unknown origin: role of immunohistochemistry in the evaluation of cutaneous metastases of carcinoma of unknown origin.
  • [MeSH-major] Adenocarcinoma / secondary. Immunohistochemistry / methods. Neoplasms, Unknown Primary / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115055.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Kato S, Yasuda K, Nishino Y, Ohori H, Takahashi M, Takahashi S, Yamaura G, Ohtsuka K, Kakudo Y, Chiba N, Shimodaira H, Sakayori M, Kato S, Suzuki T, Murakawa Y, Gamoh M, Shibata H, Yoshioka T, Ishioka C: [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases]. Gan To Kagaku Ryoho; 2007 Aug;34(8):1227-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
  • Cancer of unknown primary site (CUP) is not a rare entity and accounts for 3-5% of all malignant neoplasias.
  • CUP shows much histological and therapeutic heterogeneity.
  • Histologically, half of CUPs are adenocarcinoma and the rest are undifferentiated carcinomas.
  • We analyzed the clinical and therapeutic characteristics 22 cases of CUP patients.
  • Most CUP patients are found from lymph node swelling.
  • Because of its variety, individualized therapy may be ideal for CUP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymph Nodes / pathology. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / mortality
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Carboplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Etoposide / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Paclitaxel / administration & dosage. Prognosis. Survival Rate

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687203.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil
  •  go-up   go-down


80. Hainsworth JD, Fizazi K: Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol; 2009 Feb;36(1):44-51

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment for patients with unknown primary cancer and favorable prognostic factors.
  • Patients with carcinoma of unknown primary site are heterogeneous with respect to clinical and pathologic features.
  • Specific subsets include women with peritoneal carcinomatosis, women with isolated axillary lymph node metastases, adenocarcinoma presenting as a single metastatic lesion, young men with features of extragonadal germ cell tumor, squamous carcinoma involving cervical or inguinal lymph nodes, and neuroendocrine carcinoma.
  • [MeSH-major] Neoplasms, Unknown Primary / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179187.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 58
  •  go-up   go-down


81. Homet B, Hitt R, Ghanem I, Cortés-Funes H: Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival. Clin Transl Oncol; 2010 Aug;12(8):574-5
Genetic Alliance. consumer health - Diagnosis Unknown.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of unknown primary cancer based on molecular techniques may influence therapeutic approach and improve survival.
  • Unknown primary cancer (UPC) is a common clinical syndrome classically associated with a poor prognosis.
  • Pathological examination including immunohistochemistry continues to be essential in tumour origin characterization, although in many cases primary tumour site remains unknown.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / pathology. Spinal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1810-2 [12175699.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3766-72 [15897574.001]
  • (PMID = 20709655.001).
  • [ISSN] 1699-3055
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


82. Pimiento JM, Teso D, Malkan A, Dudrick SJ, Palesty JA: Cancer of unknown primary origin: a decade of experience in a community-based hospital. Am J Surg; 2007 Dec;194(6):833-7; discussion 837-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of unknown primary origin: a decade of experience in a community-based hospital.
  • BACKGROUND: Cancer of unknown primary (CUP) origin is a very aggressive disease with a poor prognosis.
  • Most of the literature reports of CUP are generated from tertiary cancer centers.
  • METHODS: A retrospective chart review of all patients with a diagnosis of CUP was performed between January 1995 and January 2005.
  • The pathologic diagnoses included adenocarcinoma (42.8%), undifferentiated carcinoma (34.5%), squamous cell carcinoma (9.8%), neuroendocrine cancer (6.5%), sarcoma (3.2%), and nonspecific malignant neoplasm (3.2%).
  • CONCLUSIONS: CUP encompasses a variety of different pathologic entities with an overall dismal 5-year survival.
  • Nonetheless, squamous cell and neuroendocrine CUP are associated with a significantly better early prognosis than the other malignancies.
  • [MeSH-major] Neoplasms, Unknown Primary / epidemiology
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Brain Neoplasms / secondary. Carcinoma / secondary. Carcinoma, Neuroendocrine / mortality. Carcinoma, Neuroendocrine / secondary. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / therapy. Female. Head and Neck Neoplasms / secondary. Hospitals, Community. Hospitals, Teaching. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Male. Middle Aged. Prognosis. Retrospective Studies

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005780.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Calabrese L, Jereczek-Fossa BA, Jassem J, Rocca A, Bruschini R, Orecchia R, Chiesa F: Diagnosis and management of neck metastases from an unknown primary. Acta Otorhinolaryngol Ital; 2005 Feb;25(1):2-12
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of neck metastases from an unknown primary.
  • Neck lymph node metastases from occult primary constitute about 5%-10% of all patients with carcinoma of unknown primary site.
  • Diagnostic procedures include a careful clinical evaluation and a fiberoptic endoscopic examination of the head and neck mucosa, biopsies from all suspicious sites or blindly from the sites of possible origin of the primary, computerized tomography scan, and magnetic resonance.
  • In these cases, a systematic tonsillectomy in the absence of suspicious lesions is discussed since up to 25% of primary tumours can be detected in this site.
  • Thoracic, and abdominal primaries (especially from lung, oesophagus, stomach, ovary or pancreas) should be sought in the case of adenocarcinoma and involvement of the lower neck.
  • Positron emission tomography with fluoro-2-deoxy-D-glucose allows detection of primary tumour in about 25% of cases, but this procedure is still considered investigational.
  • A potential benefit from extensive radiotherapy should be weighed against its acute and late morbidity and difficulties in re-irradiation in the case of subsequent primary emergence.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary. Neoplasms, Unknown Primary

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Mar;30(3):411-6 [12634970.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Sep;260(8):436-43 [12684829.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2003 Oct;260(9):490-3 [12739031.001]
  • [Cites] Cancer Treat Rev. 2004 Apr;30(2):153-64 [15023433.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1937-44 [15128893.001]
  • [Cites] N Engl J Med. 2004 May 6;350(19):1945-52 [15128894.001]
  • [Cites] Cancer Treat Rev. 2004 Jun;30(4):369-84 [15145511.001]
  • [Cites] Cancer. 1973 Apr;31(4):854-9 [4706050.001]
  • [Cites] Radiology. 1974 Mar;110(3):659-63 [4130047.001]
  • [Cites] Am J Surg. 1977 Oct;134(4):517-22 [911038.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1979 Jan;5(1):73-6 [422418.001]
  • [Cites] Clin Radiol. 1980 May;31(3):355-8 [7428277.001]
  • [Cites] Radiology. 1984 Sep;152(3):749-53 [6463256.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 May;12(5):733-40 [3710857.001]
  • [Cites] Otolaryngol Head Neck Surg. 1986 Jun;94(5):605-10 [3088524.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Dec;12(12):2101-10 [3793546.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):331-3 [11241001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):55-63 [11316546.001]
  • [Cites] Acta Oncol. 2001;40(1):24-8 [11321655.001]
  • [Cites] Radiother Oncol. 2001 Jun;59(3):319-21 [11369074.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):727-33 [11395241.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):535-40 [11398889.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2001 Jul-Aug;63(4):214-6 [11408815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):4-9 [11516844.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1057-8 [11583184.001]
  • [Cites] Ann Oncol. 2001 Nov;12(11):1605-9 [11822762.001]
  • [Cites] Laryngoscope. 1987 Sep;97(9):1080-4 [3626734.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):510-5 [2736495.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):289-94 [2303361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Oct;19(4):919-28 [2211260.001]
  • [Cites] Am J Surg. 1990 Oct;160(4):443-6 [2221252.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Dec;116(12):1388-93 [2248737.001]
  • [Cites] Head Neck. 1990 Nov-Dec;12(6):463-9 [2258284.001]
  • [Cites] Head Neck. 1991 May-Jun;13(3):177-83 [2037468.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(4):743-9 [1618667.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):884-90 [1495353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Mar 15;25(4):619-22 [8454479.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1756-61 [8348505.001]
  • [Cites] Head Neck. 1994 Jan-Feb;16(1):58-63 [8125789.001]
  • [Cites] Cancer Treat Rev. 1994 Apr;20(2):119-47 [8156538.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Am J Surg. 1994 Nov;168(5):395-9 [7977958.001]
  • [Cites] Laryngoscope. 1995 May;105(5 Pt 1):548-50 [7760677.001]
  • [Cites] Head Neck. 1995 May-Jun;17(3):190-8 [7782203.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1995;252(4):222-8 [7546677.001]
  • [Cites] Radiother Oncol. 1995 Jun;35(3):206-11 [7480823.001]
  • [Cites] Radiology. 1996 Jun;199(3):761-6 [8638002.001]
  • [Cites] J Laryngol Otol. 1996 Apr;110(4):353-6 [8733457.001]
  • [Cites] Ann Otolaryngol Chir Cervicofac. 1996;113(4):212-8 [9033687.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):797-802 [9128954.001]
  • [Cites] Strahlenther Onkol. 1997 Jul;173(7):362-8 [9265258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):291-6 [9308930.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1997;9(5):322-9 [9368728.001]
  • [Cites] Am J Clin Oncol. 1998 Apr;21(2):121-5 [9537194.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1998 Apr;23(2):158-63 [9597287.001]
  • [Cites] Laryngoscope. 1998 Oct;108(10):1578-83 [9778305.001]
  • [Cites] Head Neck. 1998 Dec;20(8):674-81 [9790287.001]
  • [Cites] Head Neck. 1998 Dec;20(8):739-44 [9790297.001]
  • [Cites] Laryngoscope. 1998 Nov;108(11 Pt 1):1605-10 [9818813.001]
  • [Cites] Radiother Oncol. 1998 Oct;49(1):33-40 [9886695.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):599-604 [10203278.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):114-8 [10391570.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1999 Jul;108(7 Pt 1):700-4 [10435932.001]
  • [Cites] Cancer J Sci Am. 1999 Jul-Aug;5(4):214-8 [10439166.001]
  • [Cites] Oncologist. 2005 Mar;10(3):215-24 [15793225.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Jan;122(1):52-5 [10629482.001]
  • [Cites] Int J Hyperthermia. 2000 Jan-Feb;16(1):85-93 [10669319.001]
  • [Cites] Aust N Z J Surg. 2000 Apr;70(4):263-8 [10779057.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Radiother Oncol. 2000 May;55(2):121-9 [10799723.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] Nihon Jibiinkoka Gakkai Kaiho. 2000 May;103(5):524-8 [10853340.001]
  • [Cites] Head Neck. 2000 Jul;22(4):336-40 [10862015.001]
  • [Cites] Ned Tijdschr Geneeskd. 2000 Jul 8;144(28):1355-60 [10923158.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 Sep;123(3):294-301 [10964310.001]
  • [Cites] Otolaryngol Pol. 2000;54 Suppl 31:258-61 [10974901.001]
  • [Cites] Head Neck. 2002 Mar;24(3):236-46 [11891955.001]
  • [Cites] Acta Otorhinolaryngol Belg. 2002;56(1):77-82 [11894635.001]
  • [Cites] Head Neck. 2002 Apr;24(4):361-9 [11933178.001]
  • [Cites] Curr Opin Oncol. 2002 May;14(3):323-9 [11981279.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2002 Jul;259(6):325-33 [12115082.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Aug;29(8):1024-30 [12173016.001]
  • [Cites] Acta Otolaryngol. 2002 Jul;122(5):569-74 [12206272.001]
  • [Cites] Cancer Control. 2002 Sep-Oct;9(5):387-99 [12410178.001]
  • [Cites] Laryngoscope. 2002 Nov;112(11):2009-14 [12439171.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Oral Maxillofac Surg. 2002 Dec;40(6):484-7 [12464205.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Head Neck. 2003 Feb;25(2):138-45 [12509797.001]
  • [Cites] Acta Otorrinolaringol Esp. 2002 Oct;53(8):601-6 [12530200.001]
  • (PMID = 16080309.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 102
  • [Other-IDs] NLM/ PMC2639847
  •  go-up   go-down


84. Gopaldas R, Kunasani R, Plymyer MR, Bloch RS: Hepatoid malignancy of unknown origin--a diagnostic conundrum: review of literature and case report of collision with adenocarcinoma. Surg Oncol; 2005 Jul;14(1):11-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatoid malignancy of unknown origin--a diagnostic conundrum: review of literature and case report of collision with adenocarcinoma.
  • Based on a review of literature, we discuss the guidelines for differentiating these tumors and utilize these criteria to differentiate these tumors irrespective of their primary tissue of origin.
  • We also describe an unusual case of hepatoid variant of primary peritoneal yolk sac tumor presenting with extensive carcinomatosis and as a collision with two synchronous primary colonic adenocarcinomas, neither of which has been reported to our knowledge to date, thereby falsely mimicking metastatic dedifferentiated colonic adenocarcinoma.
  • In the absence of a primary identifiable liver disease, this is consistent with either hepatoid variant of primary yolk sac tumor or hepatoid carcinoma arising from the peritoneum.
  • The right colectomy specimen revealed two mucosal ulcers consistent with colonic adenocarcinoma abutting two large tumor nodules on the serosal surface.
  • With no evidence of yolk sac component within the colonic tumor or in the draining lymphatics, this essentially excludes the commonly observed metastatic dedifferentiation (opisthoplasia) of adenocarcinoma to primitive forms (also known as combination tumors).
  • This unusual presentation of two entirely different primary malignancies in close proximity is defined as "collision tumor".
  • This is the first reported case of collision tumors involving dual colonic and primary peritoneal hepatoid-YST.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Endodermal Sinus Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Peritoneal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15777886.001).
  • [ISSN] 0960-7404
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 52
  •  go-up   go-down


85. Fernández Cotarelo MJ, Guerra Vales JM: [Therapeutic management of cancer of unknown primary site by pathological types]. Rev Clin Esp; 2009 Oct;209(9):439-43

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic management of cancer of unknown primary site by pathological types].
  • The term cancer of unknown primary site includes metastatic tumours with different histology and behaviour.
  • The treatable cases are: metastases of squamous carcinoma in cervical or inguinal adenopathies, metastases of adenocarcinoma in axilar adenopathies in women, malignant ascites due to adenocarcinoma in women, osteoblastic bone metastases in men with elevated serum prostatic specific antigen levels, poorly differentiated tumours with features of a germinal extragonadal tumour, poorly differentiated neuroendocrine carcinomas and patients with a single metastasis.
  • [MeSH-major] Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 Sociedad Española de Calidad Asistencial. Published by Elsevier España, S.L. All rights reserved.
  • (PMID = 19852914.001).
  • [ISSN] 0014-2565
  • [Journal-full-title] Revista clínica española
  • [ISO-abbreviation] Rev Clin Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Morawietz L, Floore A, Stork-Sloots L, Folprecht G, Buettner R, Rieger A, Dietel M, Huebner G: [Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification]. Pathologe; 2009 Dec;30 Suppl 2:168-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparing immunohistochemical diagnosis of cancer of unknown primary with gene expression-based tumor classification].
  • If the primary tumor cannot be identified after diagnostic workup, the disease is referred to as cancer of unknown primary (CUP) and is classified as C80.9 according to ICD-10.
  • In Germany, CUP is among the ten most common causes of tumor-related death, with mortality similar to mortality in gastric or pancreatic cancer.
  • Gene expression profiling (GEP) is a new diagnostic technique that might further contribute to tumor specification.In a retrospective study, 43 CUP cases underwent central immunohistochemical review and centrally performed GEP using a classifier based on 495 genes.
  • In four cases, the combination of methods led to an unequivocal identification of the primary tumor.In conclusion, we regard detailed IHC workup and complementary GEP advisable for the purposes of targeted therapy, as well as to identify or exclude specific tumors in a CUP situation.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenocarcinoma / secondary. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma / genetics. Carcinoma / pathology. Carcinoma / secondary. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / genetics. Immunohistochemistry / methods. Neoplasms, Unknown Primary / genetics. Neoplasms, Unknown Primary / pathology

  • Genetic Alliance. consumer health - Diagnosis Unknown.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1981 Jun 15;47(12):2923-7 [7260879.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Pathologe. 2002 May;23(3):183-97 [12089786.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Jun;54(3):243-50 [15890271.001]
  • [Cites] Virchows Arch. 2007 Jun;450(6):699-711 [17479285.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4031-40 [15899792.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1390-7 [19536816.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):221-7 [19046817.001]
  • [Cites] Lancet Oncol. 2008 Jun;9(6):596-9 [18510991.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1985-95 [14578198.001]
  • [Cites] Recent Results Cancer Res. 2008;170:193-202 [18019627.001]
  • [Cites] Strahlenther Onkol. 2008 Mar;184(3):150-6 [18330511.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4435-41 [18802156.001]
  • [Cites] Virchows Arch. 2010 Jan;456(1):23-9 [20012089.001]
  • [Cites] Br J Cancer. 2009 Jan 13;100(1):44-9 [19066607.001]
  • [Cites] Cancer. 2004 May 1;100(9):1776-85 [15112256.001]
  • (PMID = 19756615.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Hayashi Y, Nishida T, Kondo J, Yamamoto K, Iijima H, Tsutsui S, Hiramatsu N, Tsujii M, Tsuji S, Ito H, Takehara T, Hayashi N: [Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease]. Nihon Shokakibyo Gakkai Zasshi; 2009 Jan;106(1):69-76
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease].
  • Primary lesion was not detected by the surveillance of whole gastro-intestinal tract.
  • Liver tumor biopsy samples were histologicaly analyzed and were diagnosed as adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Crohn Disease / complications. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Unknown Primary / drug therapy

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122424.001).
  • [ISSN] 0446-6586
  • [Journal-full-title] Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology
  • [ISO-abbreviation] Nihon Shokakibyo Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  • [Number-of-references] 19
  •  go-up   go-down


88. Yonemori K, Ando M, Shibata T, Katsumata N, Matsumoto K, Yamanaka Y, Kouno T, Shimizu C, Fujiwara Y: Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Cancer Res Clin Oncol; 2006 Oct;132(10):635-42
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.
  • OBJECTIVES: To evaluate the usefulness of tumor-marker measurements and to identify prognostic factors in patients with cancer of unknown primary (CUP), receiving platinum-based combination chemotherapy and to verify the adjustment of previously reported prognostic models in this population.
  • METHODS: We conducted univariate and multivariate analyses in consecutive patients with CUP receiving platinum-based combination chemotherapy.
  • The ST-439 level was significantly higher in patients with histologically confirmed adenocarcinoma than in patients with poorly differentiated adenocarcinoma or poorly differentiated carcinoma.
  • CONCLUSION: Tumor-marker measurements are not helpful in the management of patients with CUP.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / therapeutic use. Cisplatin / therapeutic use. Neoplasms, Unknown Primary / drug therapy

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1994;22(3):162-7 [7505876.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Cancer. 1981 Sep 1;48(5):1242-4 [6268281.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1720-5 [7541451.001]
  • [Cites] J Clin Oncol. 1992 Jun;10(6):912-22 [1375284.001]
  • [Cites] Eur J Cancer. 1996 Dec;32A(13):2357-9 [9038622.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):297-301 [15015611.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3):286-93 [12063682.001]
  • [Cites] Cancer. 2000 Dec 15;89(12):2655-60 [11135228.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Med Sci Monit. 2002 Feb;8(2):MT25-30 [11859288.001]
  • [Cites] Cancer. 2004 May 1;100(9):1776-85 [15112256.001]
  • (PMID = 16791594.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; EC 1.1.1.27 / L-Lactate Dehydrogenase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


89. Herbst J, Jenders R, McKenna R, Marchevsky A: Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section. Am J Clin Pathol; 2009 Jan;131(1):122-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section.
  • The distinction between primary lung adenocarcinoma and metastatic breast carcinoma in patients with a history of breast cancer is difficult by frozen section (FS) analysis.
  • The pretest odds ratio of primary pulmonary carcinoma/metastatic breast carcinoma was 2.6.
  • The incidence of 12 histopathologic features was assessed in a "training set" composed of 20 FSs, 10 with primary lung adenocarcinoma and 10 with metastatic breast cancer.
  • A differential diagnosis model composed of significant pathologic features that favor the diagnosis of primary lung adenocarcinoma (acini, lepidic growth, nuclear pseudoinclusions, and scar) or metastatic breast carcinoma (comedonecrosis, solid nests, trabecular architecture, and cribriform growth) was identified.
  • The external validity of this model was successfully tested by challenging 19 pathologists and trainees with a test set of 20 unknown FSs, supporting the clinical applicability of the diagnostic model.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / pathology. Frozen Sections / methods. Lung Neoplasms / diagnosis


90. Nanni C, Rubello D, Castellucci P, Farsad M, Franchi R, Toso S, Barile C, Rampin L, Nibale O, Fanti S: Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients. Eur J Nucl Med Mol Imaging; 2005 May;32(5):589-92
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of 18F-FDG PET-CT imaging for the detection of an unknown primary tumour: preliminary results in 21 patients.
  • PURPOSE: Metastatic cancer of unknown primary origin is a syndrome characterised by a poor prognosis, with a typical survival rate from diagnosis of no longer than 1 year.
  • Only 20-27% of primary tumours are identified by conventional radiological imaging.
  • By contrast, it has been reported that 18F-fluorodeoxyglucose positron emission tomography (FDG PET) allows the identification of 24-40% of otherwise unrecognised primary tumours.
  • The aim of this study was to evaluate the potential additional diagnostic role of fused 18F-FDG PET-CT imaging for the detection of metastatic occult primary tumours.
  • RESULTS: 18F-FDG PET-CT detected the occult primary tumour in 12 patients (57% of cases), providing a detection rate higher than that reported with any other imaging modality, including conventional 18F-FDG PET.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / secondary. Image Enhancement / methods. Neoplasms, Unknown Primary / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1977 Nov;186(5):625-30 [921356.001]
  • [Cites] Nucl Med Commun. 2003 Oct;24(10 ):1081-6 [14508164.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2094-103 [7636553.001]
  • [Cites] Ann Oncol. 1991 Jul;2(7):519-20 [1911461.001]
  • [Cites] Arch Intern Med. 1988 Sep;148(9):2035-9 [3046543.001]
  • [Cites] Radiology. 1980 Feb;134(2):367-9 [7352215.001]
  • [Cites] Med Hypotheses. 2002 Sep;59(3):357-60 [12208170.001]
  • [Cites] Cancer. 1998 Mar 15;82(6):1160-6 [9506364.001]
  • [Cites] J Nucl Med. 2000 May;41(5):816-22 [10809197.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1461-7 [2207996.001]
  • (PMID = 15726356.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


91. Neeli S, Prabha V, Alur S, Malur P: Penile metastasis from primay mucinous adenocarcinoma of bladder. Indian J Urol; 2007 Jul;23(3):314-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Penile metastasis from primay mucinous adenocarcinoma of bladder.
  • Primary adenocarcinoma of the urinary bladder is not common.
  • Though penile metastases from transitional cell carcinoma are reported, such metastases from adenocarcinoma of urinary bladder is unknown.
  • We report a 55-year-old male having penile metastasis from primary mucinous adenocarcinoma of bladder.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Urol. 1998 Aug;82(2):206-12 [9722755.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1990 Apr;143(4):671-8 [2179579.001]
  • [Cites] Br J Urol. 1971 Feb;43(1):4-15 [4926456.001]
  • [Cites] J Urol. 1964 May;91:538-48 [14154540.001]
  • [Cites] J Androl. 2003 Jul-Aug;24(4):499-500 [12826689.001]
  • [Cites] Urol Oncol. 2006 Jan-Feb;24(1):13-20 [16414487.001]
  • [Cites] Cancer. 1956 May-Jun;9(3):626-32 [13330017.001]
  • [Cites] Urology. 2003 Jul;62(1):145 [12837452.001]
  • (PMID = 19718338.001).
  • [ISSN] 0970-1591
  • [Journal-full-title] Indian journal of urology : IJU : journal of the Urological Society of India
  • [ISO-abbreviation] Indian J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2721614
  • [Keywords] NOTNLM ; Adenocarcinoma / penile metastasis / urinary bladder neoplasm
  •  go-up   go-down


92. Mukai H, Katsumata N, Ando M, Watanabe T: Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer. Am J Clin Oncol; 2010 Feb;33(1):32-5
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of a combination of docetaxel and cisplatin in patients with unknown primary cancer.
  • OBJECTIVES: Evaluation of the safety and efficacy of docetaxel and cisplatin in the treatment of unknown primary cancer.
  • PATIENTS AND METHODS: Inclusion criteria included histologic evidence of carcinoma originating in an unknown primary organ, no prior chemotherapy, age range 20 to 75 years, WHO PS < or =3, measurable or evaluable lesions, and adequate organ function.
  • CONCLUSIONS: These results indicate that the combination of docetaxel and cisplatin is a safe and effective regimen for patients with unknown primary cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Neoplasms, Unknown Primary / drug therapy

  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19786850.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


93. Tagawa T, Tomita T, Yamaguchi H, Ozawa H, Sakamoto K, Ogawa K, Fujii M: [Clinical study of 28 cases of cervical lymph node metastasis from an unknown primary carcinoma]. Nihon Jibiinkoka Gakkai Kaiho; 2007 Jul;110(7):506-12
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical study of 28 cases of cervical lymph node metastasis from an unknown primary carcinoma].
  • From 1989 to 2005, 28 patients--20 men and 8 women--with cervical lymph node metastasis from an unknown primary carcinoma were treated and studied retrospectively.
  • Blind biopsy under general anesthesia was conducted in 10 patients, showing one primary tumor in the nasopharynx.
  • The histopathological diagnosis of cervical lymph node was as follows: squamous cell carcinoma in 21, adenocarcinoma in 3, mucoepidermoid carcinoma in 2, and others in 2.
  • Seven patients were found to have a subsequent primary tumor.
  • Primary tumor sites were as follows: tonsils in 3 and upper gingiva, base of tongue, lung, and nasopharynx in 1 each.
  • FDG-PET was conducted in 7 patients but revealed no primary tumor.
  • We should pay particular attention to the tonsils for detecting primary tumors in patients with cervical metastasis from an unknown primary carcinoma.
  • [MeSH-major] Head and Neck Neoplasms / secondary. Lymph Nodes / pathology. Lymphatic Metastasis / diagnosis. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17695298.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


94. Asakura H, Takashima H, Mitani M, Haba R, Seo R, Yokoe K, Toyama Y, Ohkawa M: Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine. Int J Clin Oncol; 2005 Aug;10(4):285-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.
  • Here we describe a case of IBC, which arose as an unknown primary carcinoma; the patient presented with axillary lymph node metastasis, and was successfully treated with trastuzumab and vinorelbine.
  • Although she underwent various examinations, the primary site of the disease was not revealed.
  • Axillary lymph node dissection was performed, and the lesion was diagnosed as a poorly differentiated adenocarcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / diagnosis. Breast Neoplasms / drug therapy. Neoplasms, Unknown Primary / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Axilla. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Diseases. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Receptor, ErbB-2 / metabolism. Tomography, Emission-Computed. Trastuzumab. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Arch Surg. 1990 Feb;125(2):210-4 [2302061.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):719-26 [11821453.001]
  • [Cites] Lancet. 2002 Sep 7;360(9335):790-2 [12241842.001]
  • [Cites] Science. 1989 May 12;244(4905):707-12 [2470152.001]
  • [Cites] Breast J. 2001 Nov-Dec;7(6):398-404 [11843851.001]
  • [Cites] Cancer Res. 1990 Jan 15;50(2):421-5 [1967224.001]
  • [Cites] Oncogene. 1999 Apr 1;18(13):2241-51 [10327070.001]
  • [Cites] Oncogene. 1989 Oct;4(10):1233-9 [2571966.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2889-95 [12885806.001]
  • [Cites] Surg Oncol. 1999 Jul;8(1):27-33 [10885391.001]
  • [Cites] Oncologist. 2003;8(2):141-8 [12697939.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3857-62 [12473600.001]
  • [Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]
  • [Cites] Cancer. 1990 Oct 1;66(7):1461-7 [2207996.001]
  • [Cites] Gan To Kagaku Ryoho. 1995 Nov;22(13):1933-9 [7487123.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):46-53 [12506169.001]
  • (PMID = 16136377.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5V9KLZ54CY / Vinblastine; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab; Q6C979R91Y / vinorelbine
  •  go-up   go-down


95. Matsubara N, Mukai H, Nagai S, Itoh K: Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East. Int J Clin Oncol; 2010 Dec;15(6):578-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of primary unknown cancer: cases referred to the National Cancer Center Hospital East.
  • BACKGROUND: Primary unknown cancer (PUC) is not rare neoplasm.
  • In 41 patients (32.5%), primary malignancies were identified by immunohistochemical studies and radiographical workup after referral to our hospital.
  • CONCLUSION: In about half of the patients with preliminary diagnosed PUC, the primary origin could be identified, or it was possible to distinguish subsets with favorable prognosis.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Squamous Cell / secondary. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 Jan 1;57(1):120-4 [3940611.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Semin Oncol. 1977 Mar;4(1):53-8 [841350.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Nov;23(11):1645-8 [2448145.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):421-5 [17180509.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):9-16 [14695313.001]
  • [Cites] Tumori. 1993 Oct 31;79(5):321-4 [8116074.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4442-8 [18802157.001]
  • [Cites] Oncology. 1998 Mar-Apr;55(2):116-21 [9499185.001]
  • [Cites] JAMA. 1979 Jan 26;241(4):381-3 [758556.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1810-2 [12175699.001]
  • [Cites] Postgrad Med J. 2000 Nov;76(901):690-3 [11060142.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Oncology (Williston Park). 1998 Nov;12(11A):226-309 [10028513.001]
  • [Cites] Am J Clin Oncol. 1987 Feb;10(1):82-5 [3548315.001]
  • (PMID = 20700615.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


96. Shaw PH, Adams R, Jordan C, Crosby TD: A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network. Clin Oncol (R Coll Radiol); 2007 Feb;19(1):87-95
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinical review of the investigation and management of carcinoma of unknown primary in a single cancer network.
  • AIMS: Carcinoma of unknown primary (CUP) is a common encounter in oncological practice and represents 2.0-6.0% of all invasive malignancies.
  • Evidence to support particular therapeutic strategies in this patient population is scarce, and empirical therapies are frequently derived from research on patients where the primary tumour site is known.
  • MATERIALS AND METHODS: This retrospective study reviewed the management of all patients recorded to have a diagnosis of CUP in a single cancer centre over a period of 12 months.
  • Health records were reviewed documenting the CUP subtype, the investigations carried out both in the referring cancer unit and subsequently at the cancer centre and the recommended treatment (type and regimen), together with survival.
  • RESULTS: One hundred and sixty-six patients were recorded to have a diagnosis of CUP, representing 3.7% of all referrals to the cancer centre.
  • The three most common CUP subgroups were CUP-liver/multiple sites (25.0%), CUP-bone (21.0%) and CUP-brain (16.0%).
  • Even within a single subtype, 41 patients with CUP-liver/multiple sites underwent a total of 19 different investigations before any treatment being given.
  • Nine different 5-fluorouracil-containing regimens were used in 11 patients treated with chemotherapy for CUP-liver.
  • CONCLUSIONS: The appropriate management of patients with CUP is unclear and this study revealed a high degree of variation in clinical practice.
  • This area is in urgent need of clinical research to ensure that the treatment of CUP is evidence based.
  • Therapeutic progress will be facilitated by designating a clinical lead for CUP in each clinical network.
  • [MeSH-major] Adenocarcinoma / secondary. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Liver Neoplasms / secondary. Neoplasms, Unknown Primary / therapy

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17305260.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


97. Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N: Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1. BMC Cancer; 2005 Mar 3;5:25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1.
  • BACKGROUND: Cancer of unknown primary remains a mallignancy of elusive biology and grim prognosis that lacks effective therapeutic options.
  • We investigated angiogenesis in cancer of unknown primary to expand our knowledge on the biology of these tumors and identify potential therapeutic targets.
  • METHODS: Paraffin embedded archival material from 81 patients diagnosed with CUP was used.
  • Tumor histology was adenocarcinoma (77%), undifferentiated carcinoma (18%) and squamous cell carcinoma (5%).
  • CONCLUSION: Angiogenesis is very active and expression of VEGF is almost universal in cancers of unknown primary.
  • [MeSH-major] Antigens, CD34 / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Neoplasms, Unknown Primary / chemistry. Thrombospondin 1 / analysis. Vascular Endothelial Growth Factor A / analysis
  • [MeSH-minor] Adenocarcinoma / blood supply. Adenocarcinoma / chemistry. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma / blood supply. Carcinoma / chemistry. Carcinoma / pathology. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Anticancer Res. 1998 May-Jun;18(3B):1907-14 [9677443.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):298-306 [10917542.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2826-31 [11555600.001]
  • [Cites] Eur J Cancer. 2002 Feb;38(3):409-13 [11818207.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1810-2 [12175699.001]
  • [Cites] Nat Rev Cancer. 2002 Oct;2(10):795-803 [12360282.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] Ann Oncol. 2003 Feb;14(2):191-6 [12562643.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Anticancer Res. 2004 Jan-Feb;24(1):297-301 [15015611.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1070-8 [15094121.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] World J Surg. 2004 Jun;28(6):535-9 [15366740.001]
  • [Cites] Ann Intern Med. 1986 Apr;104(4):547-53 [3006571.001]
  • [Cites] Ann Intern Med. 1989 Aug 1;111(3):213-7 [2502058.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1306-9 [2479986.001]
  • [Cites] Ann Oncol. 1992 Sep;3(8):631-4 [1450045.001]
  • [Cites] J Clin Oncol. 1994 Jun;12(6):1272-80 [8201389.001]
  • [Cites] Br J Cancer. 1996 Apr;73(7):931-4 [8611409.001]
  • [Cites] Anticancer Res. 1995 Nov-Dec;15(6B):2563-7 [8669824.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 5;89(3):219-27 [9017002.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):81-5 [9036874.001]
  • [Cites] Cancer Res. 2000 Jun 1;60(11):2898-905 [10850435.001]
  • (PMID = 15743540.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Thrombospondin 1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC555600
  •  go-up   go-down


98. Slagle WS, Eckermann DR, Musick AN, Slagle AM: Adenocarcinoma metastasis causing discrete extraocular muscle enlargement. Optometry; 2009 Jul;80(7):367-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma metastasis causing discrete extraocular muscle enlargement.
  • Clinical signs and symptoms of EOM metastasis can often be indistinguishable from primary idiopathic orbital myositis, posing a significant clinical challenge.
  • Fine-needle aspiration biopsy showed adenocarcinoma cytology in the muscle.
  • CONCLUSIONS: This case illustrates discrete adenocarcinoma metastasis of an EOM, initially displaying characteristics predominantly consistent with orbital myositis.
  • Thus, the predominant features of global orbital metastatic cancer versus primary inflammation are highlighted in this presentation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Muscle Neoplasms / diagnosis. Muscle Neoplasms / secondary. Neoplasms, Unknown Primary. Oculomotor Muscles

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545850.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Centeno BA, Bloom G, Chen DT, Chen Z, Gruidl M, Nasir A, Yeatman TY: Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site. J Mol Diagn; 2010 Jul;12(4):476-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hybrid model integrating immunohistochemistry and expression profiling for the classification of carcinomas of unknown primary site.
  • Identification of the site of origin for 'malignancy with unknown primary' remains a challenge for modern pathology.
  • Standard pathological approaches combine morphology and immunohistochemical (IHC) studies to first subclassify cytokeratin-positive carcinomas into adenocarcinoma, squamous cell carcinoma, neuroendocrine carcinoma, and urothelial carcinoma.
  • Subsequently, organ-specific IHC-markers, if available, are used to assign the tumor's primary site of origin.
  • Dependent on initial classification, one of three second-tier classifiers assign primary site resulting in both carcinoma subtype and primary site classification.
  • Second tier accuracies were 87%, 90%, and 87% for adenocarcinoma, squamous, and neuroendocrine carcinoma respectively.
  • Therefore, we can successfully separate the four main subtypes of carcinoma and subsequently assign primary site by incorporation of gene expression-based classifiers into the standard algorithmic pathology approach.
  • [MeSH-major] Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods. Models, Biological. Neoplasms, Unknown Primary / classification. Neoplasms, Unknown Primary / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Oct;157(4):1299-309 [11021834.001]
  • [Cites] Int J Cancer. 2009 Sep 15;125(6):1390-7 [19536816.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7388-93 [11606367.001]
  • [Cites] Hum Pathol. 2001 Oct;32(10):1087-93 [11679943.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] J Pathol. 2002 Jan;196(1):44-50 [11748641.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15149-54 [11742071.001]
  • [Cites] Mod Pathol. 2002 Jan;15(1):6-10 [11796835.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):5999-6005 [12414618.001]
  • [Cites] Br J Cancer. 2003 Jun 2;88(11):1746-54 [12771991.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4144-9 [12874019.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1985-95 [14578198.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):9-16 [14695313.001]
  • [Cites] Am J Surg Pathol. 2004 Oct;28(10):1371-8 [15371954.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3063-71 [15833835.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4031-40 [15899792.001]
  • [Cites] Arch Pathol Lab Med. 2006 Apr;130(4):465-73 [16594740.001]
  • [Cites] J Mol Diagn. 2006 Jul;8(3):320-9 [16825504.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Oct 20;349(2):825-32 [16945327.001]
  • [Cites] Clin Cancer Res. 2007 May 15;13(10):2905-15 [17504990.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):415-20 [18091384.001]
  • [Cites] Hum Pathol. 2008 Apr;39(4):591-8 [18284937.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):462-9 [18362881.001]
  • [Cites] Br J Cancer. 2008 Apr 22;98(8):1425-30 [18414470.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4435-41 [18802156.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4442-8 [18802157.001]
  • [Cites] Pathol Int. 2008 Nov;58(11):681-6 [18844932.001]
  • [Cites] Conf Proc IEEE Eng Med Biol Soc. 2008;2008:2419-22 [19163190.001]
  • [Cites] Diagn Cytopathol. 2009 Mar;37(3):178-83 [19170169.001]
  • [Cites] Am J Surg Pathol. 2009 Apr;33(4):626-32 [19065104.001]
  • [Cites] Mod Pathol. 2009 May;22(5):709-17 [19287461.001]
  • [Cites] J Clin Oncol. 2009 May 20;27(15):2503-8 [19332734.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1231-8 [11583950.001]
  • (PMID = 20558571.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA076292; United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2893632
  •  go-up   go-down


100. Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM: Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site. Cancer; 2007 Aug 15;110(4):770-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
  • BACKGROUND: The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP).
  • METHODS: Patients with CUP received carboplatin AUC 5 mg/mL a minute intravenously Day 1, gemcitabine 1000 mg/m(2) intravenously Days 1 and 8, and capecitabine 1600 mg/m(2) orally in divided doses, Days 1-14 of a 21-day cycle for up to 8 cycles.
  • The primary endpoint of the study was objective response rate by intent-to-treat analysis.
  • The objective response rate was 39.4% (95% CI, 22.9%-57.9%) in all patients, 36.4% in 22 patients with well to moderately differentiated adenocarcinoma, and 40.0% in 20 patients with liver metastases.
  • CONCLUSIONS: The combination of carboplatin, gemcitabine, and capecitabine is active in CUP, especially in patients with liver metastases.
  • This regimen may be a potential therapy for CUP patients with good performance status, particularly those with a suspected origin below the diaphragm.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17594717.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement